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Abstract
A PKCα-mediated growth suppressive MEK-ERK signaling axis in
intestinal epithelial cells
Navneet Kaur, Ph.D.
University of Nebraska Medical Center, 2021
Supervisor: Dr. Jennifer D Black
Members of the protein kinase C (PKC) family of serine/threonine kinases are involved in
regulation of fundamental cellular functions, including proliferation, differentiation, survival,
migration, and transformation. Increasing evidence points to anti-proliferative and tumor
suppressive role of PKCs. Our laboratory and others have reported that the classical PKC isozyme,
PKCα negatively regulates proliferation and tumorigenesis in the intestinal epithelium. Our
laboratory has further determined that PKCα signaling induces a program of cell cycle withdrawal
in intestinal epithelial cells that involves downregulation of the pro-proliferative proteins, cyclin
D1 and Id1, and upregulation of the cyclin dependent kinase (CDK) inhibitor, p21 Cip1.
Unexpectedly, the growth inhibitory effects of PKCα are dependent on activation of the MEK-ERK
pathway, which is also a well-established mediator of pro-proliferative signaling in normal
intestinal cells and in colon cancer. The overall goal of this study was to define the mechanistic
basis of this novel PKCα-induced growth suppressive ERK signaling cascade. Based on the tumor
promoting effects of ERK signaling, ERK pathway inhibitors are being used in the clinic to manage
a broad range of tumors including colon cancer, with intestinal toxicity being a major side effect.
Thus, characterization of the growth/tumor suppressive PKCα→ERK signaling axis will (a)
enhance our understanding of growth suppressive ERK signaling, (b) point to potential strategies
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to avoid and/or manage side-effects of ERK pathway inhibitors, and (c) open new avenues for
therapeutic intervention in colon cancer.
This thesis explores (a) the involvement of canonical ERK pathway components, including
Ras, Raf, MEK, and ERK, in PKCα growth inhibitory signaling, (b) point(s) of intersection
between PKCα and the ERK pathway and the signaling intermediates that link PKCα activation to
ERK, and (c) how PKCα engagement of the ERK pathway differs from that of a pro-proliferative
signal such as epidermal growth factor (EGF).
These studies have revealed that PKCα activates each component of the canonical Ras–
Raf–MEK–ERK cascade, as seen with pro-proliferative factors such as EGF, and that activation of
these molecules is required for regulation of the downstream effector proteins, cyclin D1, Id1 and

p21Cip1, and induction of cell cycle arrest. Thus, PKCα and EGF both intersect the ERK pathway
at the level of Ras, a finding that clarifies longstanding confusion in the PKC field regarding the
requirement for Ras in PKC-mediated ERK activation. However, PKCα and EGF diverge in the
mechanism of Ras activation. While EGF is known to require the Ras guanine exchange factors
(RasGEFs) SOS1/2 for Ras activation and increased proliferation, PKCα directly or indirectly
phosphorylates and activates the RasGEF, RasGRP3, for Ras stimulation of growth-suppressive
ERK-signaling. PKCα–RasGRP3 specifically activates H-Ras to induce ERK-dependent
upregulation of the cell cycle inhibitory protein, p21Cip1, and K-Ras or N-Ras are not required for

p21Cip1 induction. Thus, the data identify a novel growth inhibitory PKCα–RasGRP3–H-Ras–
Raf–MEK–ERK–p21Cip1 pathway in intestinal epithelial cells. This pathway partially mediates
PKCα-mediated growth arrest; however, complete cell cycle arrest requires additional regulatory
events, such as downregulation of cyclin D1 and Id1, that can be mediated by K-Ras or N-Ras.
Notably, the finding that effects of PKCα on cyclin D1 and Id1 are not dependent on the RasGRP3–
H–Ras module indicates that PKCα activates at least two Ras–ERK-dependent signaling pathways
to promote growth arrest in intestinal epithelial cells. This study also revealed that PKCα forms a
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complex with all three Raf proteins in unstimulated cells, suggesting a model in which PKCα
activation serves to concentrate Raf at the plasma membrane for activation by Ras. The data further
show that there is redundancy among Raf isoforms in mediating PKCα-induced growth arrest,
while ruling out a requirement for the Raf-MEK-ERK scaffold proteins KSR1/2.
In conclusion, this study has identified a novel PKCα-induced growth suppressive MEKERK signaling cascade in normal intestinal epithelial cells that involves a RasGRP3–H-Ras–Raf–
MEK–ERK–p21Cip1 signaling axis. However, p21Cip1 only partially contributes to PKCα-mediated
G1→S arrest, and additional Ras–ERK signaling pathway(s) are clearly required for the effect.
These findings set the stage for studies to identify additional regulatory events in this novel growth
suppressive pathway.
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INTRODUCTION
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1.1 The Protein Kinase C Family
1.1.1 Three Classes of PKCs Protein Kinase C (PKC) was first identified in 1977 by Nishizuka
and colleagues as a protein kinase activity in fractions of bovine and rat brain (Inoue et al., 1977)
(Takai et al., 1977). Subsequent studies have determined that PKC comprises a family of 10
serine/threonine kinases, which belong to the AGC kinase superfamily (i.e., kinases related to
cAMP-dependent protein kinase 1 (PKA), c-GMP-dependent protein kinase (Le Good et al., 1998),
and protein kinase C (PKC)) (Hanks and Hunter 1995). Based on sequence homology and cofactor
requirements, PKCs have been divided into three classes, each containing multiple isozymes. The
classical or conventional PKCs (Nakashima, 2002) include PKCα, PKCβ (with two splice variants,
PKCβI and PKCβII), and PKCγ; the novel PKCs (Rahimova et al., 2020) include PKCδ, PKCε,
PKCη, and PKCθ; and the atypical PKCs (Lamark et al., 2003) include PKCι (known as PKCλ in
mouse), and PKCζ. As discussed in further detail below, the cPKCs are lipid-dependent protein
kinases that require diacylglycerol (DAG), phosphatidylserine and Ca 2+ for activity. The nPKCs
require DAG and phosphatidylserine but not Ca2+ for activity, and the aPKCs do not require either
DAG or Ca2+ and are activated by protein-protein interactions (Table 1).
Class of PKC

PKC Isozyme

Co-activators

Conventional PKCs

PKCα, PKCβΙ/βΙΙ and PKCγ

DAG, PS, Ca2+

Novel PKCs

PKCδ, PKCε, PKCθ and PKCη

DAG, PS

Atypical PKC

PKCι (known as λ in mice) and PS
PKCζ

Table 1: PKC classification based on co-factor requirements
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Fig 1-1: Classification of PKCs based on their structure and domains
Three classes of PKCs, cPKCs, nPKCs and aPKCs, share structural similarities at their Cterminal while differing in their regulatory N-terminal domains and requirement for co-factors
for activation. (Adapted from Mackay et al, 2007)
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1.1.2 Structure of PKCs All PKC isozymes share structural similarities, with the kinase domain at
the carboxyl-terminus (~45 kDa), a flexible hinge region connecting the kinase domain to an Nterminal regulatory domain (~20-70 kDa), and an autoinhibitory pseudosubstrate domain (Parker
and Murray-Rust, 2004) (House and Kemp, 1987) (Mochly-Rosen, 1995) (Fig 1-1). Within this
overall structure, there are several conserved regions designated C1 through C4 which are separated
by four variable regions, V1 - V4 (Ono et al., 1988) (Coussens et al., 1986) (Knopf et al., 1986)
(Parker et al., 1986). The C3 and C4 domains, which harbor the ATP-binding and substrate-binding
motifs in the catalytic domain, respectively, are highly conserved amongst all PKC isozymes and
are related to those seen in other AGC kinases. In contrast, the C1 and C2 domains, which represent
the co-factor binding domains, are divergent between the different PKC classes.
C1 domains are cysteine-rich zinc finger containing motifs that bind membrane DAG.
Originally identified in PKCs, C1 domains are present in multiple signaling families, including
protein kinase D, RasGRPs and DAG kinases (Blumberg et al., 2008). Classical and novel PKCs
have tandem C1 domains, C1a and C1b, with only one domain binding DAG in the context of the
full-length protein. While the C1a subdomain of both PKC classes has high affinity for DAG, the
C1b domain of cPKCs has 2 orders of magnitude lower affinity for DAG than the C1b domain of
nPKCs (Dries et al., 2007), contributing to differences in the activation requirements of these
kinases (see below).
C2 domains are lipid binding modules found in cPKCs and nPKCs that target the kinases
to cell membranes. Like C1 domains, C2 domains are found in multiple proteins including
phospholipases, PIK3C2A, PIK3C2B, PTEN and synaptotagmins. C2 domains show broad
selectivity for the major lipid components of cell membranes; in PKCs, they bind to
phosphatidylserine. The C2 domain of cPKCs is a Ca2+ sensor that coordinates Ca2+ binding,
increasing the affinity of the domain for membranes. Novel PKCs harbor a variant C2 domain
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(novel C2) that lacks residues that coordinate Ca2+; thus, novel PKCs are insensitive to Ca2+ and
are regulated only by DAG.
In contrast to the cPKCs and nPKCs, aPKCs lack a C2 domain and their C1-like domain
contains only one cysteine-rich region that does not bind DAG. Instead, the aPKCs have
Phox/Bem1-protein interacting domains in the regulatory region, which mediate protein-protein
interactions that provide the regulatory forces to drive their activation (Lamark et al., 2003)
The pseudosubstrate sequence, which is common to all PKCs, plays a central role in
regulating PKC activity (House and Kemp, 1987), maintaining PKCs in an inactive state by
occupying the substrate-binding cavity. It consists of an optimal sequence for binding to the
substrate pocket but lacks the phosphorylatable residue (House and Kemp, 1987); thus, when it
occupies the active site, it prevents substrate binding, keeping the kinase in a closed and inactive
conformation (House and Kemp, 1987) (Orr and Newton, 1994).
1.1.3. Priming Phosphorylation of PKC Newly synthesized PKC proteins are in an open
conformation that is highly susceptible to proteasomal degradation, and are catalytically
incompetent. Catalytic competence of PKCs requires priming phosphorylation on three sites in the
C-terminal domain: the activation loop site (Thr497 of PKCα), the turn motif site (Thr638 of
PKCα), and the hydrophobic motif site (Ser657 of PKCα). Newly synthesized PKCs migrate to the
plasma membrane, where these phosphorylations occur in a highly regulated and ordered process
(Parekh et al., 2000). The first priming event involves phosphorylation of a threonine residue in the
activation loop of the kinase domain by phosphoinositide-dependent kinase (PDK-1) (Chou et al.,
1998; Dutil et al., 1998; Le Good et al., 1998). This phosphorylation initiates the maturation process
and is necessary for subsequent priming phosphorylations (Dutil and Newton, 2000; Dutil et al.,
1998). The second priming phosphorylation is in the turn motif, which is located in the carboxyl
tail. This phosphorylation requires mammalian target of rapamycin complex 2 (Baffi et al., 2021)
(Facchinetti et al., 2008; Ikenoue et al., 2008). The last priming event is the autophosphorylation
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of the hydrophobic motif, also in the C-terminal tail, by a process that is modulated by both heat
shock protein 90 (HSP90) and mTORC2 (Gould et al., 2009; Ikenoue et al., 2008; Ziegler et al.,
1999). A recent study by the Newton group has identified an additional priming phosphorylation
motif, the mTOR interaction motif or TIM (Baffi et al., 2021). Phosphorylation of this motif by
mTORC2 allosterically regulates PDK-1 binding, activation loop phosphorylation, and
autophosphorylation of the hydrophobic motif (Baffi et al., 2021). The fully phosphorylated PKC
is released into the cytosol, with the pseudosubstrate domain occupying the substrate binding cavity
and maintaining the kinase in an inactive, closed conformation (Newton, 2010; Newton, 2018). In
contrast to the unphosphorylated protein, fully primed PKC is highly resistant to proteasomal
degradation, and the mature protein has a half-life >48 h prior to activation. It should be noted that
these phosphorylation events are constitutive and do not contribute directly to enzyme activation:
as such, in contrast to other AGC kinases, phosphorylation at priming sites does not provide an
indication of the activation status of PKCs.
1.1.4. Physiological Activation of PKCα
As noted above, fully primed PKCs reside in the cytoplasm in an inactive state, with the
pseudosubstrate domain occupying the substrate binding site. Activation of PKCs involves release
of the pseudosubstrate domain as a consequence of interaction with the plasma membrane.
Extracellular signals that trigger activation of phospholipase C (PLC), such as ligand or agonist
binding to G-protein coupled receptors (Gq) or receptor tyrosine kinases (Vivanco et al., 2010),
lead to hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) in the plasma membrane and
generation of inositol 1,4,5-triphosphate (IP3) and DAG. Through interaction with their C1
domains, DAG recruits both cPKCs and nPKCs to the plasma membrane, allowing the C2 domain
to interact with phosphatidylserine. Following engagement of the C1 and C2 domains with
membrane phospholipids, cPKCs and nPKCs partially insert into the membrane and this provides
the energy which drives release of the pseudosubstrate domain and kinase activation. Thus,
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membrane association represents the key activating event for PKCs and is the most reliable
indicator of kinase activation (Kraft et al., 1982).
Due to the low affinity of the C1b domain for DAG, activation of PKCα and other cPKCs is a twostep process. Although the C1a domain has high affinity for DAG, the C1a domain of unstimulated
PKCα is masked by interaction with the C2 and catalytic domains and is only released for DAG
binding following Ca2+-dependent interaction of the C2 domain with anionic lipids in the plasma
membrane (Farah and Sossin, 2012; Slater et al., 2002; Stahelin et al., 2005). Thus, activation of
PKCα involves its initial recruitment to the membrane by the C2 domain, which then leads to
release of the C1a domain for DAG binding. The C2 domain has a low intrinsic affinity for Ca 2+,
but Ca2+ binding is enhanced by DAG, phosphatidylserine, and phosphatidylinositol 4,5bisphosphate in the plasma membrane, allowing for activation by DAG even at subphysiological
intracellular Ca2+ levels (Antal et al., 2014; Egea-Jiménez et al., 2013; Igumenova, 2015; Stahelin
et al., 2005). Nonetheless, while activation of PKCα by DAG does not require release of
intracellular calcium stores, elevated intracellular Ca2+ concentrations increase the rate of PKCα
activation in the presence of DAG (Stahelin et al., 2005). As mentioned above, membrane
translocation represents the key activating event for PKCs and is a hallmark of its activation (Kraft
et al., 1982). At the same time, the IP3 generated by PLC binds to receptors in smooth endoplasmic
reticulum (ER) and promotes release of Ca2+ in the cytoplasm, thus enhancing activation of cPKCs.
DAG is rapidly metabolized in the plasma membrane by DAG kinases and DAG lipases, which
results in acute termination of PKC activity following ‘reverse translocation’ and redistribution of
the kinase to the cytoplasm (Akita, 2002; Di Mari et al., 2005; Leitges et al., 1996; Lum et al.,
2016). Pharmacological agents such as phorbol esters also recruit cPKCs and nPKCs to the plasma
membrane through their C1 domains. However, these agents are not readily metabolized, inducing
prolonged activation of these PKCs and ultimately resulting in chronic loss, or downregulation of
the kinases (Newton, 2018)(Fig 1-2).
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Fig 1-2: Sequential activation of PKCs
Newly synthesized, degradation-sensitive PKC, which is in an open conformation (i),
undergoes a series of ordered phosphorylations facilitated by Hsp90, Cdc37, the kinase complex
mTORC2, and the activation loop kinase, PDK-1.

Phosphorylated cPKC adopts an

autoinhibitory conformation, where the Ca2+ sensing C2 domain clamps the autoinhibitory
pseudosubstrate segment and masks the DAG sensing C1 domain, thereby preventing basal
signaling in the absence of agonist (ii). Upon agonist binding to Gq-coupled receptors, for
example, phospholipase C (PLC) is hydrolyzed to generate DAG and Ca 2+. Ca2+ promotes
recruitment of PKC to plasma membrane by engaging the C2 domain (iii). PKC binds to
membrane-embedded DAG via the C1 domain, releasing the autoinhibitory pseudosubstrate
sequence (Voldborg et al.). This active PKC can phosphorylate downstream substrates and
carry out downstream signaling. PKC returns to an autoinhibited conformation following the
decay of second messenger DAG. A sequential dephosphorylation by PHLPP and PP2A can
produce a fully dephosphorylated PKC in some contexts, which is degraded by proteasomal
degradation (v) (Newton, 2018)
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1.1.5. Pharmacological Activators and Inhibitors PKCα
1.1.5.1. PKC Agonists Multiple natural compounds have been shown to modulate the activity of
PKCs, with phorbol esters and bryostatins being the most widely studied agonists. Phorbol esters
are the active component derived from croton oil (Van Duuren and Sivak, 1968), the most
commonly used being phorbol 12-myristate 13-acetate (PMA), also known as 12-Otetradecanoylphorbol 13-acetate (TPA), and phorbol 12,13-dibutyrate (Knopf et al., 1986).
Bryostatins are a family of macrolide lactones isolated from bryozoans (Kraft et al., 1982), the best
known of which is bryostatin 1. As noted above, these agonists bind promiscuously to the C1
domains of both cPKCs and nPKCs. Thus, although they do not activate aPKCs, they show no
specificity for individual cPKCs or nPKCs. Notably, phorbol esters and bryostatins bind with high
affinity to the C1b domain of PKCα and other cPKCs; thus, activation by these agents does not
involve the two-step process outlined for cPKCs above.
Another group of agonists used to pharmacologically activate PKCs are short-chain DAGs,
such as 1,2-dioctanoyl-sn-glycerol (DiC8). Because of their increased solubility compared with
endogenous long chain DAGs, these agents can be applied to the culture medium to activate cellular
PKCs. Like the phorbol esters and bryostatins, these short-chain DAGs promiscuously activate
cPKCs and nPKCs. Since the domain interacting moiety of short-chain DAGs is identical to that
of endogenous PKC agonists, these compounds represent a more physiological approach for PKC
activation. However, due to their rapid metabolism in the membrane by DAG kinases and DAG
lipases (Eichmann and Lass, 2015), short-chain DAGs have the disadvantage that they have to be
added repeatedly to induce sustained PKC activation. Phorbol esters and bryostatins, on the other
hand, are not rapidly degraded in the membrane, providing sustained activation following a single
addition (Huang et al., 1986; Leontieva and Black, 2004 Huang et al., 1989).
1.1.5.2. PKC Inhibitors Much of our knowledge of PKC signaling has been derived from the use
of pharmacological inhibitors. A number of small molecule ATP-competitive inhibitors of PKC
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have been developed based on bisindolylmaleimides or indolocarbazoles. For instance, the
bisindolylmaleimide, bisindolylmaleimide I (Sipeki et al., 2006), and the indolocarbazole, Gö6983,
show selectivity against PKC compared with other kinases (Wu-Zhang and Newton, 2013).
However, these inhibitors do not differentiate between PKC isozymes; thus, while use of these
agents can indicate that PKC is involved in a particular pathway, by themselves they do not provide
information regarding the specific involvement of individual PKCs. Furthermore, many
bisindolylmaleimides and indolocarbazoles such as Ro-31-8220, Ro-32-0432, and staurosporine
that have been used for PKC inhibition are, in fact, relatively non-selective (Wu-Zhang and
Newton, 2013) (Anastassiadis et al., 2011; Davis et al., 2011) (Karaman et al., 2008). Therefore,
data obtained using these agents needs to be interpreted with caution.
Although development of inhibitors that are selective for PKCs in general has been
successful, the high degree of conservation within PKC catalytic domains has presented an obstacle
to the development of inhibitors that can discriminate between individual PKC isozymes. Despite
this caveat, some inhibitors have been developed that show selectivity for a particular PKC
subgroup. For example, the indolocarbazole, Gö6976, is selective for inhibition of cPKCs over
nPKCs and aPKCs (Anastassiadis et al., 2011; Bain et al., 2007; Davies et al., 2000).
In the quest to develop more specific inhibitors, compounds are being designed which
target less conserved domains of PKC. For example, the bisindolylmaleimide, BisIV, has been
developed as a non-active site inhibitor of PKC; however, this is also a general PKC inhibitor and
lacks the potency of Bim I. Other non-active-site inhibitors targeting the DAG binding site (Puente
et al., 2000), the PKC priming kinases PDK-1 and mTORC2, or the maturation process by
inhibiting HSP90 (17-AAG), have also been employed to inhibit PKC activity. Along with weak
PKC inhibition, these agents have off-target effects and inherently lack specificity for PKCs.
It is important that careful consideration be used in selection of inhibitors for PKC
isozymes since historic literature and company marketing can often be misleading. For example,
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although Rottlerin has been widely used as a selective inhibitor for PKCδ, and is still marketed on
these grounds, this compound does not inhibit the kinase activity of PKCδ. Thus, experiments using
Rottlerin cannot be used to infer new roles for PKCδ since any effects of this compound on PKCδ
signaling must, at best, be indirect (Maioli et al., 2012; Soltoff, 2007).
Despite these caveats, when combined with additional tools, such as characterization of the
PKC expression profile of the cells being examined, siRNA-mediated knockdown, etc., PKC
inhibitors offer powerful tools for dissecting the roles of PKC isozymes in cellular signaling.
1.1.6. PKC Degradation - Turning off the Signal
PKC signal termination is mediated by acute inactivation and long-term desensitization
mechanisms. As discussed above, acute signal reversal is largely accomplished through rapid
metabolism of DAG by DAG kinases and/or DAG lipases (Eichmann and Lass, 2015), which leads
to activity-dependent dissociation of PKC from the membrane and restoration of the autoinhibited
protein in the cytosol (Feng and Hannun, 1998; Gould and Newton, 2008). However, prolonged
activation by ligands that are not readily metabolized (Denning et al., 1995) or by physiological
stimuli can result in marked downregulation of PKC protein, leading to loss of associated signaling
in the continued presence of agonists. Multiple mechanisms have been implicated in this effect,
particularly in the case of PKCα which has been more extensively studied, with subcellular
localization playing a major role in dictating the engagement of existing processing pathways.
While ubiquitin-mediated proteasomal degradation at the plasma membrane is a major mechanism
mediating long-term desensitization of PKCs (Lee et al., 1996; Lee et al., 1997b; Leontieva and
Black, 2004; Lu et al., 1998), endomembrane trafficking and lysosomal processing have also been
shown to play a role, at least for PKCα (Lum et al., 2013b; Melnikov and Sagi-Eisenberg, 2009;
Prevostel et al., 2000).
Multisite dephosphorylation by cellular phosphatases such as PH domain Leucine-rich
repeat Protein Phosphatase (Gao et al., 2008) and protein phosphatase 2A (Hansra et al., 1999;

11

Leontieva and Black, 2004) may serve as a trigger for PKC degradation in some contexts. Loss of
phosphate at a single site predisposes the other sites to dephosphorylation (Bornancin and Parker,
1996; Bornancin and Parker, 1997) and the dephosphorylated protein is highly susceptible to
proteasomal degradation. However, fully phosphorylated, mature enzyme is the major substrate
for the proteasome in many cell types (Leontieva and Black, 2004; Lum et al., 2013a; Prevostel et
al., 2000; Srivastava et al., 2002). Although few studies have addressed lysosomal pathways of
PKC processing, PKCα has been shown to be internalized via at least two distinct lipid raftdependent pathways (distinguished by dynamin dependence) and the fully primed protein is the
only target for lysosomal degradation (Lum et al., 2013a; Prevostel et al., 2000).
While cPKCs and nPKC are degraded in response to prolonged activation by phorbol
esters, studies with other PKC agonists have identified important differences in desensitization of
these enzymes by chronic activation. While nPKCs such as PKCδ and PKCε are readily degraded
in response to prolonged activation by membrane-permeant short chain DAGs (Lum et al., 2016)
or physiological signals that stimulate the production of DAG (e.g., gonadotropin-releasing
enzyme, bombesin, and PDGF) (Maccario et al., 2004; Olivier and Parker, 1994), chronic activation
of cPKCs by DiC8 or physiological agonists such as thyrotropin releasing enzyme and angiotensin
II fails to engage desensitization mechanisms such as dephosphorylation, ubiquitination,
internalization, or degradation, with the enzyme remaining membrane-associated and able to
support sustained downstream signaling for prolonged periods (e.g., 12 hours) (Chiu et al., 2003;
Kiley et al., 1991; Lum et al., 2016; Olivier and Parker, 1994). Differences in Ca2+ sensitivity and
DAG affinity were excluded as mediators of the selective resistance of cPKCs, with limited
evidence suggesting that differential membrane compartmentalization may be involved (Lum et al.,
2016). The differential effects of PKC agonists on cPKCs and nPKCs may reflect their activation
at different cellular locations, with PKCα translocating mainly to the plasma membrane while
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PKCδ accumulates in a variety of additional compartments for activation (Newton, 2010),
including Golgi membranes, the endoplasmic reticulum, mitochondria, and the nucleus.
1.2 Functions of PKC
1.2.1. PKCs: Tumor Promoters or Tumor Suppressors?
Early studies by Nishizuka’s group in Japan identified PKCs as the major cellular receptors for
tumor promoting phorbol esters such as PMA/TPA, which binds cPKCs and nPKCs at the same
site as DAG and potently activates these kinases (see above) (Castagna et al., 1982; Kikkawa et al.,
1983). TPA/PMA is a major component of the widely used two-stage model of skin carcinogenesis,
which involves a single, sub-carcinogenic application of the chemical initiator mutagen 7,12dimethylbenz[a]anthracene followed by repeated applications of TPA (Hara et al., 2005). The link
to the two-step skin cancer model identified by Nishizuka’s group led to the widely held notion that
PKCs are tumor promoting kinases. This, in turn, led to years of intensive efforts to inhibit PKCs
for cancer treatment. However, these efforts have been largely unsuccessful, reflecting significant
complexity in the cellular functions of PKCs. Over the years since the discovery of PKC, studies
in multiple systems have linked these kinases to regulation of a plethora of fundamental cellular
processes, including cell cycle progression, differentiation, cell survival, apoptosis, and migration,
processes which are disrupted in cancer (Antal et al., 2015; Rahimova et al., 2020), diabetes,
pancreatitis, and Alzheimer’s disease (Alfonso et al., 2016) among other diseases. Dysregulated
PKC signaling can also lead to drug resistance in cancer (Mackay and Twelves, 2007). PKCs have
also been linked to tumor suppression in many tissue types.
1.2.2 PKC in Regulation of the Cell Cycle and Cell Survival PKC signaling regulates a wide
variety of cellular processes including cell proliferation, survival, differentiation, migration, and
transformation. However, individual knockdown of PKC isozymes in mice is not lethal, except in
the case of PKCι, indicating that PKCs can generally compensate for the loss of an individual
family member (Abeliovich et al., 1993; Castrillo et al., 2001; Hodge et al., 1999; Leitges et al.,
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2001; Leitges et al., 1996; Martin et al., 2002; Mecklenbräuker et al., 2002; Miyamoto et al., 2002;
Suzuki et al., 2003). Such functional redundancy has complicated studies to pin-point the roles of
individual PKC isozymes. Furthermore, the same isozyme has been found to play different or
opposing roles in different cell types. For example, PKCα appears to be oncogenic in certain breast
cancer subtypes (Wang et al., 2018) but acts as a tumor suppressor in intestinal epithelial and
endometrial cells (Hsu et al., 2018; Oster and Leitges, 2006a; Pysz et al., 2009).
Extensive studies support a role for PKCs in regulation of the cell cycle and cell survival.
Progression through the cell cycle is driven by the enzymatic activity of cyclin dependent kinases
(Black and Black, 2012), regulated by their associated cyclins, whose levels are determined by the
cellular environment (e.g., mitotic signals or DNA damage) (Otto and Sicinski, 2017). PKC
signaling can have negative or positive effects on cell cycle progression, primarily at the G1/S and
G2/M transitions. The cell cycle consists of four phases, G1, S, G2, and M. In G1 phase, the pocket
proteins pRb (retinoblastoma protein), p107 and p130 bind to E2F transcription factors, recruiting
histone deacetylases (HDAC) and other factors to inhibit transcriptional activity of growth-related
genes. These genes (e.g., PCNA, topoisomerase I, c-Myc, cyclin E, Cdc25c) are important for cell
cycle progression into S phase and DNA replication. Mitogenic signals induce the expression of
D-type cyclins, leading to formation of cyclin D/Cdk4 and cyclin D/Cdk6 complexes via a
mechanism that is facilitated by Cip/Kip Cdk inhibitors (Ckis). This leads to phosphorylation of
pRb (partial), releasing HDACs and other inhibitory factors and thereby relieving E2F repression
and promoting upregulation of cyclin E (Cobrinik, 2005). The formation of cyclin E/Cdk2
complexes completes the phosphorylation and inactivation of pocket proteins, triggering a program
of transcriptional events necessary for S phase entry (Malumbres and Barbacid, 2005). Together,
these events result in overcoming the restriction point (Fig 1-3, large red arrow), which commits
cells to the proliferative cycle. However, in the case suboptimal conditions or loss of mitogenic
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signal, cells exit the cell cycle and enter G0 or quiescence, a reversible non-replicative state (Fig 13, adapted from (Black and Black, 2012)).
Once the cells enter S phase, cyclin E undergoes proteosome-mediated degradation to
avoid re-initiation of DNA replication. Simultaneously, continued hyperphosphorylation/inactivation of pocket proteins allows the transcription of cyclin A and cyclin B. Cyclin A
forms complexes with Cdk2, which phosphorylates several proteins to facilitate S phase completion
and transition to G2/M. As the cells progress through G2, cyclin A is degraded coincident with
active synthesis and accumulation of cyclin B. cyclin B/Cdk1 complexes trigger mitosis (Fig 1-4
adapted from (Black and Black, 2012)).
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Fig 1-3: Mechanistic view of cycle progression through G1 phase
In early G1, E2F activity is repressed by pocket proteins (like Rb). Upon growth factor signaling,
formation of cyclin D/Cdk4/6 complexes leads to phosphorylation of pocket proteins and relief of
E2F repression. Active E2F induces the expression of cyclin E and subsequent assembly of active
cyclin E/Cdk2 complexes, which complete phosphorylation of pocket proteins to enable passage
through the restriction point (red arrow). E2F then transcribes genes important for S phase
progression (adapted from (Black and Black, 2012)).
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Fig 1-4: Regulation of the cell cycle
During S phase, cyclin E undergoes proteasomal degradation and transcription of cyclins A and B
is initiated. Cyclin A/Cdk2 complexes facilitate S phase completion and transition to G2/M phase,
while cyclin B synthesis is continued through G2 phase to trigger mitosis. A checkpoint in late G2
(green arrow) prevents cells from entering cells into M phase in the case of DNA damage (adapted
from (Black and Black, 2012)).
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Regulation of cell cycle progression by PKC signaling is highly dependent on the timing and
duration of PKC activation, the PKC isozyme(s) involved, and the cellular environment. PKCs
have been shown to regulate the cell cycle by modulating the expression of D-type cyclins
(especially cyclin D1) and the Cdk inhibitors, p21Cip1 (p21) and p27Kip1 (p27) (Fig 1-5), as well as
lamin B in G2/M (Fig 1-6, (Black and Black, 2012). In some systems, PKC activation in early G1
leads to increased transcription of cyclin D1 (Li et al., 2006a; Soh and Weinstein, 2003) and
destabilization of p21 (Walker et al., 2006), resulting in hyperphosphorylation of pocket proteins
and cell cycle progression into S phase. However, activation of PKC in mid-to-late G1 results in
downregulation of D-type cyclins via transcriptional as well as translational repression (Hizli et al.,
2006; Pysz et al., 2009; Soh and Weinstein, 2003) and transcriptional induction of p21 and p27
(Black and Black, 2021; Griner and Kazanietz, 2007). Together, these effects result in inhibition
of cyclin D/Cdk4/6 and cyclin E/Cdk2 complex activity, and cell cycle arrest in G0/G1 phase.
In some systems, lamin B, an essential protein for nuclear structure and function, is
phosphorylated by PKCβII in G2. PKC-mediated phosphorylation of lamin B results in disassembly
of the nuclear envelope, allowing cells to enter M phase and proceed with chromosome segregation
(Taylor et al., 2013). Alternatively, PKCs can negatively regulate the G2/M transition by
downregulating the phosphatase Cdc25 and preventing the dephosphorylation and activation of
Cdk1 (Arita et al., 1998; Barth and Kinzel, 1994; Kosaka et al., 1993). PKC can also cause a delay
in the G2/M transition by inducing p21 levels through an ERK-dependent mechanism (Arita et al.,
1998; Barboule et al., 1999; Frey et al., 1997; Oliva et al., 2008).
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Fig 1-5: PKC-mediated regulation of G1/S phase
PKC
can regulate the G1-S transition both positively (upper portion of the figure) as well as
progression
negatively (lower portion of the figure). In early G1, PKC activation can increase cyclin D1 levels
and destabilize p21, leading to hyperphosphorylation of pocket proteins (Cobrinik, 2005) and
progression into S phase. However, activation of PKC in mid-late G1 reduces cyclin D1 levels while
elevating p21 and p27, resulting in hypophosphorylation of pocket proteins and cell cycle
withdrawal into G0.

19

Fig 1-6: Regulation of the G2/M phase transition by PKC
PKC signaling has opposing effects on G2/M progression. PKC-mediated phosphorylation of
nuclear lamins promotes nuclear lamina disassembly and G2/M transition as shown here in the
upper portion of the figure. Alternatively, PKC can inhibit progression of cells into M phase via
inhibition of the Cdc25 phosphatase, blockade of Cdk1 dephosphorylation and accumulation of
p21.
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PKC signaling has also been implicated in regulation of cell survival/apoptosis. Apoptosis
is important for maintenance of tissue homeostasis and to prevent diseases involving abnormal cell
growth such as cancer. There are two main pathways of apoptosis, the extrinsic and intrinsic
pathways, defined by their upstream initiation signals. The extrinsic pathway involves activation
of death receptors (TRAILR or Fas) and the intrinsic pathway is initiated by stimuli that trigger
cytochrome c release from the mitochondria (Fig 1-7) (Ichim and Tait, 2016). PKCα/ε and PKCδ
have opposing regulatory roles in apoptosis, highlighting unique functions of individual PKC
isozymes in some cellular processes (Griner and Kazanietz, 2007; Reyland, 2010). PKCε is known
to activate ERK and AKT mitogenic pathways (Lu et al., 2006), leading to upregulation of the prosurvival factors, BCL-XL and XIAP, and thereby protecting cells against TRAIL-induced
apoptosis (Pardo et al., 2006). The pro-survival functions PKCα, in turn, appear to involve
modulation of BCL-XL and BCL2. In contrast, PKCδ can promote both intrinsic as well as
extrinsic apoptotic pathways. DNA damage can cause PKCδ to undergo caspase-3 mediated
proteolysis, freeing the catalytic domain, which then translocates to the nucleus and induces
phosphorylation of apoptotis-related substrates (Bharti et al., 1998; Cross et al., 2000; Frasch et al.,
2000; Yuan et al., 1998). PKCδ can also serve as a positive feedback signal to trigger intrinsic
apoptosis. PKCδ can translocate to mitochondria and contribute to release of cytochrome c, further
amplifying caspase-3 activation (Denning et al., 2002; Li et al., 1999; Majumder et al., 2000).
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Fig 1-7: PKCδ-mediated apoptosis
DNA damage, either by exposure to UV or DNA-damaging agents, can lead to cleavage of PKCδ
by caspase-3. The constitutively active catalytic domain of PKCδ can then translocate to the
mitochondria to induce release of cytochrome c to initiate intrinsic apoptosis (left panel).
Alternatively, cleaved PKCδ can translocate to the nucleus and phosphorylate substrates involved
in apoptosis. Full length PKCδ can also initiate extrinsic apoptosis by modulating the response of
death receptors (right panel) (Griner and Kazanietz, 2007)
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1.2.3 Other Cellular Functions of PKC
The two splice variants of PKCβ, PKCβI and PKCβII, are transcribed from a common gene
(Patel et al., 2004), and are expressed in many normal tissues. PKCβ is important in maintaining
immune functions by promoting B-cell survival and activation of NF-κB signaling (Saijo et al.,
2002; Su et al., 2002). Both PKCβI and PKCβII are required for B cell activation; PKCβ-/- mice
have reduced levels of B-1 lymphocytes in the peritoneum, and these B cells are defective in
producing cellular and humoral immunity (Leitges et al., 1996). Chronic activation of PKCβII has
been implicated in various pathologies, including cancer, heart disease, hyperglycemia-induced
diabetes, cardiomyopathy, neuropathy, and vascular disease (Borghini et al., 1994; Bowling et al.,
1999; Harja et al., 2009; Inoguchi et al., 1992; Leitges et al., 2001; Roberts and McLean, 1997;
Wallace et al., 2014).
In normal tissues, PKCγ is expressed in neuronal cells, where it plays a role in regulating
learning and memory (Yamaguchi et al., 2006) as well as motor-coordinated responses to pain in
the central nervous system and in spinal cord cells (Dempsey et al., 2000; Malmberg et al., 1997;
Martin et al., 1999). Missense mutations in PKCγ can contribute to Type 14 spinocerebellar ataxia
(Shuvaev et al., 2011) by causing apoptosis of Purkinje cells (Shuvaev et al., 2011). PKCγ
expression has been noted in cancer cells. In this regard, overexpression of PKCγ in mammary
epithelial cells promoted proliferation and a more invasive neoplastic phenotype, with cells
becoming resistant to cell death and producing colonies in soft agar (Mazzoni et al., 2003).
Conversely, aberrant PKCγ expression observed in some B cell lymphomas correlates with positive
prognosis (Kamimura et al., 2004).
PKCδ is expressed in most normal tissues, with pro-apoptotic (see section 1.2.2), promigratory (Reyland et al., 1999) and differentiation-inducing (Mischak et al., 1993) roles in normal
cells. PKCδ also prevents mast cell degranulation and is important in B-cell maturation and
differentiation (Yamaguchi et al., 2006). In cancer, PKCδ can have opposing effects depending on
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the tumor type. It can act as tumor suppressor in colon and skin but is known to promote cell
survival and proliferation in breast and lung cancer cells (Pabla et al., 2011). Elevated PKCδ levels
in breast and non-small cell lung cancer cells can result in anchorage-independent cell growth and
metastatic potential, as well as chemoresistance and survival (Jackson and Foster, 2004).
In normal cells, PKCε primarily prevents apoptosis and promotes cell growth (see section
1.2.2). In the myocardium, PKCε is involved in inducing normal growth and development, and in
protecting myocardial cells during ischemic preconditioning (Ardehali, 2006; Chen et al., 2001;
Ping et al., 2002; Saurin et al., 2002). In neurons, PKCε promotes neurite outgrowth, cell
proliferation, and cell differentiation and is also involved in the pain response. In brain, PKCε
expression is low in Alzheimer’s disease, where it suppresses Alzheimer-promoting β-amyloid
protein (Kinouchi et al., 1995), and in macrophages, PKCε is important for IgG-stimulated
phagocytosis of bacteria (Larsen et al., 2000).
Expression of PKCη shows a restricted pattern in normal tissues. The kinase is highly
expressed in normal skin, intestine and lung tissue, whereas a low level of PKCη is found in spleen
and brain (Koizumi et al., 1993). PKCη is involved in cytoskeletal remodeling and organization, as
its constitutive expression induces plasma membrane extensions and membrane ruffling while
reducing the number of stress fibers (Resnick et al., 1998). In T-cells, PKCη is required for
maturation of CD8+ cells and for cell proliferation following antigen stimulation (Fu et al., 2011).
In keratinocytes, PKCη promotes G1 arrest and differentiation and acts as tumor suppressor
(Kashiwagi et al., 2002; Kashiwagi et al., 2000). Thus, in normal cells PKCη can play growth
promoting as well as growth suppressive roles. However, in MCF-7 breast cancer cells PKCη is
anti-apoptotic, activating Raf-1 to promote drug resistance (Luparello et al., 2013).
PKCθ plays a crucial role in T-cell signaling, maintaining T helper cell function, and PKCθ
deficient mice fail to mount an immune response (Berg-Brown et al., 2004; Dempsey et al., 2000;
Thuille et al., 2005). In mature T cells, PKCθ is required for survival and proliferation (Barouch-
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Bentov et al., 2005). PKCθ is also required for the differentiation of T-cells into different lineages
and is involved in platelet activation to promote clotting (Cohen et al., 2011; Marsland et al., 2004;
Salek-Ardakani et al., 2004).
PKCι (known as λ in mice) is expressed in most tissues and is anti-apoptotic, preventing
UV-induced cell death (Dempsey et al., 2000). PKCλ/ι is important in promoting the formation of
adherens junctions and tight junctions, thereby establishing cell polarity (Nagai-Tamai et al., 2002;
Suzuki et al., 2003; Suzuki et al., 2002; Suzuki et al., 2001). PKCλ/ι is a known oncogene in various
cancers, where its increased levels correlate with worse prognosis and poor clinical outcome. The
kinase promotes carcinogenesis and chemoresistance in chronic myeloid leukemia, colon cancer,
non-small cell lung cancer, and ovarian cancer by stimulating signaling cascades such as Rasmediated signaling and Bcr-Abl-induced transformation (Fields and Regala, 2007; Jamieson et al.,
1999; Jin et al., 2005; Murray et al., 2004; Zhang et al., 2006).
PKCζ is also expressed in most normal tissues and is responsible for mortality and
maturation of CD34+ hematopoietic stem cells and progenitor cells (Petit et al., 2005). It acts as a
tumor suppressor, promoting differentiation and suppressing anchorage independent growth. Loss
of PKCζ in colonocytes results in a transformed phenotype and colon tumor formation (Mustafi et
al., 2006). In CaCo2 colon cancer cells, overexpression of PKCζ blocks anchorage independent
growth, increases differentiation, and increases apoptosis. Also, in MDA-MB-468 breast cancer
cells, overexpression of PKCζ inhibits tumor cell growth (Mao et al., 2000; Sun et al., 2005).
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1.2.4 Protein Kinase C α (PKCα) Signaling and Functions
1.2.4.1 Protein Kinase C α (PKCα) Signaling
PKCα is a ubiquitously expressed member of the classical subclass of PKC isozymes. As discussed
in section 1.1.4, cPKCs like PKCα are activated by DAG (in the presence of Ca 2+ and
phosphatidylserine) and phorbol esters. In the laboratory, PKCα can be activated by membrane
permeant analogs of DAG, such as DiC8, and by pharmacological agents such as PMA and
bryostatin 1. The activity of PKCα can be inhibited by the pan-PKC inhibitor Bim I and by Gö6976,
which is selective for cPKCs. Inactive PKCα is maintained in the cytosol. DAG or pharmacological
agonists (e.g., PMA) recruit the enzyme to the plasma membrane, where its autoinhibitory
conformation is relieved and the enzyme is activated for downstream signaling. Thus, plasma
membrane association of PKCα is considered a hallmark of its activation. PKCα signal termination
can occur through DAG metabolism or through agonist-induced downregulation. Work from the
Black laboratory has determined that PKCα is highly resistant to downregulation by prolonged
DAG-mediated activation (Lum et al., 2016), and sustained activation of PKCα has been linked to
cell growth arrest and differentiation of cells in epithelial tissues such as intestine (Frey et al., 1997;
Saxon et al., 1994; Verstovsek et al., 1998), skin (Tibudan et al., 2002), and endometrium (Hsu et
al., 2018).
1.2.4.2 Protein Kinase C α (PKCα) Functions
The functions of PKCα signaling have been investigated in normal cells and in multiple tumor
types. These studies highlight significant complexity and context-dependence of the signaling roles
of PKCα (Sun and Rotenberg, 1999; Zeng et al., 2002). PKCα activity has been linked to positive
and negative regulation of cell proliferation, cell cycle progression, and tumorigenesis in different
systems. However, as discussed below, the preponderance of evidence supports a role for this
isozyme in mediating cell growth arrest, differentiation, and tumor suppression (Black and Black,
2021). PKCα signaling has also been linked to cell survival, and pro-survival functions of the kinase
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appear to involve modulation of Bcl2 family members, including BCL2 and BCL-XL (Ruvolo et
al., 1998). A large literature supports the involvement of PKCα signaling in regulation of motility
and migration in normal cells. Consistent with these roles, aberrant PKCα signaling has been linked
to epithelial-to-mesenchymal transition (EMT), invasion, and metastasis in some tumor types
(Anilkumar et al., 2003; Humphries et al., 2014; Lim et al., 2003). This functional complexity
suggests that PKCα acts as a molecular sensor that can promote or repress cell proliferation,
survival, migration, and differentiation in response to specific environmental stimuli. In this regard,
it has been suggested that the responses of PKCα (and other PKCs) are not an intrinsic property of
the kinase, but instead reflect dynamic interactions of the enzyme with cell-specific factors such as
anchoring proteins, upstream modulators, and substrates (Nakashima, 2002).
Growth Regulatory Roles of PKCα: The most detailed analysis of growth regulatory roles
of PKCα in normal cells comes from studies in the hematopoietic system and in regenerating
epithelia (e.g., the intestinal lining, the epidermis, and the endometrial epithelium).
PKCα appears to have both pro- and anti-proliferative/differentiation-inducing effects in
cells of the immune system (Dieter and Schwende, 2000; Nakagawa et al., 2012; Pfeifhofer et al.,
2006). Although transgenic mice overexpressing wild-type PKCα in thymocytes did not show
altered thymocyte proliferation in vivo, when these thymocytes were isolated from the mice, their
phenotype supported a pro-proliferative role of the kinase (Iwamoto et al., 1992). In contrast, PKCα
activation in primary hematopoietic progenitor cells (Pierce et al., 1998) or a mouse myeloid
progenitor cell line (Mischak et al., 1993) provided a signal for differentiation into mature
macrophages. In hematological malignancies, PKCα has been reported to have growth inhibitory
and tumor suppressive roles. Expression of kinase-dead PKCα in hematopoietic progenitor cells in
mice led to the development of B cell chronic lymphocytic leukemia-like disease (Nakagawa et al.,
2006). In addition, PKCα promoted cytostasis and megakaryocytic differentiation of K562 human
erythroleukemia cells (Hocevar et al., 1992; Murray et al., 1993) and differentiation of THP-1
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monocytic leukemia cells into macrophage-like cells (Dieter and Schwende, 2000), with antisenseinduced deficiency of the enzyme enhancing the proliferation of the cells.
Studies of regenerating epithelia support a predominant role of PKCα in regulation of antiproliferative and tumor suppressive signaling (Frey et al., 2000; Frey et al., 1997; Hao et al., 2011;
Saxon et al., 1994). In non-transformed intestinal epithelial cells, sustained activation of PKCα
induces the expression of the cdk inhibitors p21 and p27 and rapidly downregulates D-type cyclins
(such as cyclin D1), driving cells to exit the cell cycle (Clark et al., 2004; Frey et al., 2000). These
findings are consistent with evidence that PKCα is activated coincident with cell growth arrest in
the mid-to-upper crypt region (Frey et al., 2000; Frey et al., 1997; Hao et al., 2011; Jiang et al.,
1995; Saxon et al., 1994; Verstovsek et al., 1998). PKCα signaling also suppresses the expression
of the mitogenic transcriptional regulator, inhibitor of DNA binding protein 1 (Id1), in intestinal
cells (Hao et al., 2011). Consistent with these findings, PKCα is tumor suppressive in the intestine
and colon. The enzyme is lost in >60% of human colorectal tumors (Kahl-Rainer et al., 1994; KahlRainer et al., 1996; Suga et al., 1998; Verstovsek et al., 1998) and in murine models of intestinal
neoplasia (Hao et al., 2011; Klein et al., 2000; Oster and Leitges, 2006a). Restoration of PKCα
activity in CRC cells suppresses anchorage-independent growth in vitro and tumor formation in
vivo (Batlle et al., 1998; Pysz et al., 2009), while loss of PKCα increases cell proliferation,
decreases differentiation, and enhances the transformed phenotype of colon cancer cells (Abraham
et al., 1998; Scaglione-Sewell et al., 1998). Loss of PKCα in the ApcMin/+ mouse model of intestinal
neoplasia (Oster and Leitges, 2006b) resulted in an increased number of tumors in the intestine,
with lesions displaying a more aggressive histopathological phenotype.
Similar findings have been reported in skin and in the endometrial epithelium. PKCα
mediates differentiation of keratinocytes induced by Ca2+ (Denning et al., 1995; Yang et al., 2003),
a finding that is consistent with immunohistochemical data showing that PKCα is activated in
suprabasal keratinocytes of the human epidermis, coincident with differentiation-associated growth
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arrest (Bollag, 2009; Tibudan et al., 2002). Additionally, PKCα triggers irreversible cell cycle
withdrawal in keratinocytes in association with induction of p21 and p27 and activation of pocket
proteins (Bollag, 2009; Jerome-Morais et al., 2009; Tibudan et al., 2002). As in the intestine, the
vast majority of evidence supports a tumor suppressor role for PKCα in the skin (Hara et al.,

2012).
Immunohistochemical analysis also points to an anti-proliferative role of PKCα in normal
murine endometrium epithelium (Hsu et al., 2018), with PKCα expression and activity markedly
increasing coincident with progesterone-induced growth arrest and differentiation during late
proestrus and estrus. However, in vitro studies using endometrial cancer cell lines have given
conflicting results. PKCα knockdown in some endometrial cancer cells has been reported to result
in reduced growth, fewer colonies in soft agar, and impaired xenograft formation in mice (Haughian
and Bradford, 2009; Haughian et al., 2009). In contrast, a recent report from the Black laboratory
showed inhibition of anchorage-independent growth by PKCα in a large panel of endometrial
cancer cell lines (Hsu et al., 2018) as well as potent tumor suppression by PKCα in a murine model
of mutant PTEN-driven endometrial tumorigenesis (Hsu et al., 2018). Consistent with this role,
PKCα expression is lost at early stages of endometrial tumor development and loss of the kinase is
associated with accelerated tumor development in mice and worse disease outcome in patients (Hsu
et al., 2018).
Analysis of PKCα Functions in the Mammary Epithelium and Breast Cancer Highlights
Context-dependent Effects of the Kinase: Studies in the mammary epithelium and breast cancer
cells point to a high degree of complexity in the functions of PKCα in breast tissues and illustrate
the challenges in ascribing specific roles to the kinase. In some mammary epithelial cell lines,
elevated levels of PKCα promote anchorage-independent growth in vitro and tumorigenesis in vivo
(Ways et al., 1995; Zeng et al., 2002). In others, overexpression of PKCα suppresses cell
proliferation, leading to accumulation of cells in G1 phase (Cho and Talmage, 2001; Cho et al.,
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1997; Sun and Rotenberg, 1999). Analysis of PKCα expression in patient samples has also provided
conflicting results. Several studies have shown that the kinase is upregulated in breast tumors, and
high expression has been linked to estrogen/progesterone receptor negative and triple negative
status, tamoxifen resistance, advanced stage and poor survival (Assender et al., 2007; Hsu et al.,
2014; Lahn et al., 2004; Lønne et al., 2010; Pham et al., 2017; Tonetti et al., 2012; Tonetti et al.,
2003). PKCα overexpression can reduce estrogen receptor (ER) levels, suggesting a role of the
kinase in regulating the switch between ER-positive to ER-negative status in breast cancer (Tonetti
et al., 2012; Tonetti et al., 2003). However, other studies show that PKCα is downregulated in
breast tumors (Ainsworth et al., 2004; Kerfoot et al., 2004), and that expression is lower in more
advanced disease (Ainsworth et al., 2004). These discrepancies likely reflect the heterogeneity of
the disease and differential expression of PKCα in the breast cancer subtypes analyzed in these
reports. Interestingly, analysis of a large panel of breast tumors representative of all histological
sub-types revealed that the vast majority (72%) are PKCα negative and that smaller subgroups with
higher PKCα levels display more aggressive clinicopathological features (Lønne et al., 2010).
While few studies have addressed the involvement of PKCα in metastasis, PKCα downregulation
in triple negative breast cancer cells suppressed metastasis in an orthotopic mouse xenograft tumor
model (Humphries et al., 2014). The ability of PKCα to promote tumor progression and metastasis
in breast cancer likely reflects the well documented ability of PKCα signaling to mediate cell
survival, migration, and EMT (Anilkumar et al., 2003; Humphries et al., 2014; Lim et al., 2003)
(Ruvolo et al., 1998) (Black and Black, 2021).
1.2.4.3 Mechanisms Involved in PKCα Regulation of Cell Proliferation and the Cell Cycle
Available evidence from studies in multiple cell types points to D-type cyclins and the cdk
inhibitory proteins, p21 and p27, as critical cell cycle regulatory targets of PKCα. PKCα induces
rapid downregulation of cyclins D1, D2 and D3 and/or induction of p21/p27, inhibition of G1/S
cyclin/Cdk complex activity, and changes in the pocket proteins, p107, pRb, and p130,
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characteristic of G1 arrest and cell cycle withdrawal in multiple cell types (Detjen et al.; Frey et al.,
1997; Jerome-Morais et al.). Inhibitory effects of PKCα signaling on cell proliferation/cell cycle
progression also reflect its ability to suppress signaling from tyrosine kinase receptors, including
the EGFR (Bao et al., 2000; Friedman et al., 1984; Hunter et al., 1984; Koese et al., 2013a; Lin et
al., 1986; Macdonald-Obermann and Pike, 2009; Santiskulvong and Rozengurt, 2007), ErbB2
(Ouyang et al., 1998; Ouyang et al., 1996), cMet (hepatocyte growth factor receptor) (Kermorgant
et al., 2004) and RET (Andreozzi et al., 2003). PKCα can inhibit tyrosine kinase receptor signaling
by (a) reducing ligand-binding affinity though direct receptor phosphorylation, and (b) altering cell
surface expression of receptors via modulation of receptor trafficking. PKCα can also regulate cell
proliferation by acting downstream of growth factor receptors, as exemplified by its ability to
regulate insulin action through inhibition of PI3K-AKT and MEK-ERK signaling downstream of
the insulin receptor (Caruso et al., 1999; Nawaratne et al., 2006; Oriente et al., 2005). PKCαmediated inhibition of PI3K/AKT signaling has been observed in multiple systems (Guan et al.,
2007; Hoshino et al., 2012; Hsu et al., 2018; Tanaka et al., 2003) and can be accomplished via
distinct mechanisms, including suppression of the catalytic activity of PI3K by phosphorylation of
the p84α regulatory subunit (Hoshino et al., 2012) or direct phosphorylation of the catalytic subunit
(Sipeki et al., 2006), and by PP2A-dependent dephosphorylation of AKT (Hsu et al., 2018). PKCα
can also induce growth arrest via strong and sustained activation of the ERK/MAPK pathway and
the growth inhibitory PKCα-ERK signaling module is dominant over growth-promoting ERK
signaling induced by serum growth factors (Clark et al., 2004; Wen-Sheng and Jun-Ming, 2005).
1.2.4.4 Perspectives on the Functions of PKCα Signaling
Studies in normal tissues indicate that PKCα is generally antiproliferative and/or differentiation
inducing, with suppressive effects on growth factor receptor signaling and cell cycle progression
through G1/S and G2/M phases being major underlying mechanisms (Fig 1-8). This activity is
reflected in a predominantly tumor suppressive role of the enzyme, supported by frequent
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downregulation of PKCα mRNA and protein in most cancer types (Neilsen et al., 2019) and the
finding that PKCα knockout or inhibition leads to enhanced tumorigenesis in all genetic mouse
cancer models reported to date (i.e., models of intestinal, skin, endometrial, and lung cancer as well
as B-CLL) (Hara et al., 2005; Hill et al., 2014; Hsu et al., 2018; Nakagawa et al., 2006; Nakagawa
et al., 2012; Oster and Leitges, 2006a). However, pro-proliferative functions have also been
reported, most notably in the hematopoietic system. Similarly, important tumor promoting effects
are seen in some solid cancer types, especially in breast tumors and gliomas, likely due to aberrant
activation of well documented functions of PKCα in mediating cell survival and migration in
normal cells.
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Fig 1-8: Overall summary of PKCα signaling functions in various cancers
Adapted from (Black and Black, 2021).
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1.3 ERK Signaling
1.3.1. Mitogen-Activated Protein Kinase Pathways Mitogen-activated protein kinases (MAPKs)
were first discovered as microtubule-associated protein kinase and were later named to reflect their
broader role in the cell (Boulton et al., 1991; Boulton et al., 1990; Hoshi et al., 1988; Ray and
Sturgill, 1987). MAPKs are widely expressed across tissues, conserved across species, and act as
central building blocks in intercellular signaling networks (Bogoyevitch and Court, 2004; Kuida
and Boucher, 2004; Raman and Cobb, 2003; Rubinfeld and Seger, 2005). They are divided into
four classes: the Extracellular Signal-Regulated Kinases (ERKs), the Jun N-terminal Kinases
(JNKs), p38 Kinases and the Big Mitogen-Activated Protein Kinases (BMKs). Canonical
transmission of signals via MAPKs involves a cascade involving sequential phosphorylation and
activation of cytoplasmic protein kinases. Each cascade is composed of three to five tiers in which
a MAPK kinase kinase kinase (MAP4K) phosphorylates and activates a MAPK kinase kinase
(MAP3K), which in turn phosphorylates and activates a MAPK kinase (MAP2K), which then
phosphorylates and activates the MAPK. The MAPK can then phosphorylate substrates or
additional kinases that themselves can propagate the signal. Together, MAP3K, MAP2K and
MAPK constitute the core cascade. Details of the components of the four distinct MAPK cascades
involving each of the families of MAPK, together with their most common physiological effects,
are outlined in Fig 1-9 (Shaul and Seger, 2007).
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Fig 1-9: MAPK signaling pathway
Four distinct human MAPK pathways have been identified, regulating various cellular outcomes
(adapted from (Akinleye et al., 2013; Zhang and Liu, 2002).
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1.3.2. The ERK Signaling Cascade The ERK signaling pathway represents one of the major
signaling pathways that transmit extracellular signals to promote physiological changes in the cell.
The initial step in this pathway is ligand-induced activation of cellular receptors such as G-protein
coupled receptors or receptor tyrosine kinase (RTK) receptors. Receptor activation in turn leads to
activation of the small GTPase Ras proteins, followed by activation of Raf kinases which are the
MAP3Ks in this pathway (Hoshi et al., 1988; Pawson, 2002). The activated Raf kinases then
phosphorylate and activate MAPK/ERK kinases (MEKs), the MAP2Ks, which then phosphorylate
the ERK MAPKs (Fig 1-10) (McKay and Morrison, 2007).
1.3.3. Ras Proteins Mammalian cells express three Ras proteins: H-Ras, K-Ras and N-Ras, named
after their homology to viral oncogenes (Cox and Der, 2010). Ras proteins are the founding
members of a superfamily of small GTPases which consists of at least 154 members, subdivided
into five families based on sequence identity and function: Ras, Rho, Rab, Arf and Ran families
(Wennerberg et al., 2005). These small GTPases act as molecular switches, which are regulated by
binding to guanine nucleotides. An ~20 kDa N-terminal core domain of Ras proteins contains five
conserved guanine nucleotide consensus sequence elements that are involved in phosphate/Mg 2+
and guanine nucleotide binding and make up the active site for GTP hydrolysis (Vetter and
Wittinghofer, 2001). This domain also contains two flexible regions, designated switch I and switch
II, that take on different conformations depending on whether GTP or GDP is bound (Vigil et al.,
2010). The C terminus of Ras proteins also has a short hypervariable (HV) sequence that terminates
in a CAAX motif that signals for farnesyl or geranylgeranyl isoprenylation of the cysteine residue,
removal of the AAX residues and carboxylmethylation of the prenylated cysteine (Vigil et al.,
2010). This isoprenylation anchors mature Ras to cellular membranes where it performs signaling
functions.
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Fig 1-10: The core Ras-ERK pathway
Adapted from (Lavoie et al., 2020)
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The signaling function of Ras proteins is mediated by changes in their ability to interact
with effector proteins via a process that is regulated by binding to GDP and GTP; thus, Ras proteins
act as switchable molecular docking sites. When bound to GDP, Ras proteins adopt an inactive
conformation which is unable to interact with its effectors. However, conformation changes in
switch I and switch II that occur upon binding of GTP expose effector binding sites, and Ras is
then able to bind downstream signaling molecules such as Raf kinases (Schmidt and Hall, 2002;
Vetter and Wittinghofer, 2001). Switching between the GTP- and GDP-bound states is dictated by
the intrinsic GTPase and guanine nucleotide exchange activities of Ras proteins. By converting
bound GTP to GDP, the GTPase activity inactivates Ras proteins. In contrast, release of GDP leads
to its replacement with GTP since GTP is present at a 10-50-fold higher concentration in the cell
(Bos et al., 2007; Goldberg, 1998; Trahey and McCormick, 1987).
1.3.4. Regulation of Ras Activity The activity of Ras is regulated by its GTP hydrolysis and by
guanine nucleotide exchange. However, due to the low intrinsic GTPase activity of Ras proteins
and their high affinity for guanine nucleotides, these processes are too slow to allow for the rapid
cycling between active GTP-bound and inactive GDP-bound states required for efficient signal
transduction. This allows for fine-tuning of Ras activity by regulatory proteins that enhance GTPase
activity or release of GDP. As such, a group of proteins known as Guanine nucleotide Exchange
Factors (GEFs) activate Ras by enhancing release of a GDP. In contrast, GTPase Activating
Proteins (GAPs) promote inactivation of Ras by enhancing conversion of GTP to GDP (Jun et al.,
2013) (Fig 1-11).
1.3.5. RasGEFs As noted above, GEFs activate Ras proteins by promoting exchange of GDP for
GTP. While inhibition of GAPs and engagement of GEFs both lead to increased Ras activity,
evidence points to GEFs as the major mechanism of signal-mediated Ras activation (Hennig et al.,
2015; Vigil et al., 2010). Mammalian cells express three classes of Ras-GEFs: Sos proteins (Sos1,
Sos2), the RasGRFs (RasGRF1, RasGRF2), and the RasGRPs, (RasGRP1, RasGRP2, RasGRP3,
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RasGRP4) (Fig 1-12). All of these proteins share a CDC25 homology domain that interacts with
the switch domains of GDP-bound Ras proteins and induce a conformational change that reduces
the affinity for GDP (Toma-Fukai and Shimizu, 2019). Subsequent binding of GTP leads to release
of the GEF and enables effector binding. Outside of the CDC25 homology domain, Ras-GEF
families are differentiated by the presence of further domains with known or predicted functions
such as lipid binding (PH, C1) or calcium-binding (IQ, EF). While members of each Ras-GEF
family share similar domain structures, it is unclear if GEFs can substitute for each other. For
example, Ras activation in response to the G-protein-coupled receptor (GPCR) agonist fMLP in
neutrophils is mediated by RasGRP4, and this function cannot be substituted by RasGRP3 or any
of the other Ras-GEF in the cells (Sos1, Sos2, RasGRF1) (Suire et al., 2012). Similarly, SOS
proteins cannot substitute for RasGRP1 to activate Ras following CD25-mediated T cell activation
(Roose et al., 2007).
A major mechanism by which Ras-GEF activity is regulated during signal transduction is
through the recruitment of these molecules to the membrane, which puts the CDC25 homology
domain into juxtaposition with membrane anchored Ras proteins. This is illustrated by the role of
SOS proteins in RTK mediated activation of Ras, the best characterized example of Ras-GEF
regulation. The proline-rich domain at the C-terminus of SOS proteins interacts with adaptor
proteins such as Grb2, Shc/Grb2, Shp2, and Frs-2. Following activation of RTKs, these adaptor
proteins recruit the Ras-GEF to the tyrosine phosphorylated RTK or other membrane located
tyrosine phosphorylated proteins (e.g., IRS1) (Bernards and Settleman, 2007; Bos et al., 2007;
Cherfils and Zeghouf, 2013). In addition, interaction of other SOS domains with membrane lipids,
Ras, and other signaling constituents contributes to SOS activation by relieving autoinhibition
(Hennig et al., 2015; Toma-Fukai and Shimizu, 2019). For RasGRP proteins, membrane
recruitment is mediated by binding of C1 domains to DAG (Stone, 2011), and for RasGRFs, the
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PH1, coiled-coiled, and IQ domains are involved in activation-induced relocation (FernándezMedarde and Santos, 2011).
1.3.5. RasGAPs RasGAPs are also multidomain proteins that fall into five families:
p120GAP/RASA1, neurofibromin, the GAP1 subfamily, the SynGAP family, and plexins (Fig. 13).
These proteins all contain a conserved GAP-related domain (GRD) that is responsible for their
catalytic activity, in addition to other domains such as C2, SH2, SH3, PH, and Sec14 domains (Fig.
13). The GRD domain contains an arginine finger that is inserted into the active site of Ras to
promote catalysis, while the other domains in Ras-GAPs mediate their membrane recruitment and
modulate their function (Scheffzek and Shivalingaiah, 2019).
Unlike the clearly defined roles for Ras-GEFs in signal transduction, the precise role of
Ras-GAPs in regulation of Ras-mediated signaling remains to be firmly established and it is unclear
whether they act as primary signal transducers or modulators of Ras activation (Hennig et al.,
2015). For example, neurofimbromin is rapidly degraded by the ubiquitin proteasome pathway in
response to a variety of growth factors, pointing to a potential role for this Ras-GAP in signalinduced Ras activation (Cichowski et al., 2003; McGillicuddy et al., 2009). However, evidence also
suggests that neurofibromin may be involved in regulating the magnitude and duration of RAS
activation (Cichowski et al., 2003).
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Fig 1-11: Regulation of Ras by GEFs and GAPs
Ras shuttles between an active Ras-GTP state to a GDP-bound inactive Ras-GDP state, controlled
by guanine nucleotide exchange factors (GEFs), which stimulate exchange of GDP for GTP, and
by GTPase-activating proteins (GAPs), which terminate the active state by stimulating GTP
hydrolysis (Bos et al., 2007; Tcherkezian and Lamarche-Vane, 2007). GEFs and GAPs are both
multidomain proteins. Many of these domains interact with lipids and proteins, indicating that they
serve as localization signals and/or as scaffolds for the formation of protein complexes (Bos et al.,
2007). There are multiple RasGAPs and GEFs in cells (Fig 1-12, 1-13). (Adapted from Jun et al.,
2013)
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Fig 1-12: List of Ras GEFs
(Adapted from (Bos et al., 2007)).

Fig 1-13: List of Ras-GAPs
(Adapted from (Scheffzek and Shivalingaiah, 2019)).
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1.3.6. Raf Activation The regulation of Raf kinases is highly complex, involving alterations in
subcellular localization, protein and lipid interactions, and changes in phosphorylation (Terrell and
Morrison, 2019). In unstimulated cells, Raf proteins are localized in the cytoplasm as inactive
monomers. They are maintained in the inactive state by a number of mechanisms, including
autoinhibitory interaction of the regulatory domain with the catalytic domain, phosphorylation of
negative regulatory sites, and binding of inhibitory proteins such as 14-3-3 (Fig 1-14). Upon
pathway activation, activated GTP-loaded RAS recruits Raf proteins to the plasma membrane
through direct interaction with the Ras-binding domain (RBD) in the terminal region of Raf. Ras
binding does not directly activate Raf but rather acts to relocalize the inactive cytosolic Raf
monomers to the plasma membrane. Notably, this relocalization is the key step in the activation of
Raf since Raf proteins that are artificially targeted to the membrane are constitutively active
(Leevers et al., 1994; Stokoe et al., 1994). Membrane interaction of the Raf cysteine-rich domain
(CRD), which contains a typical zinc finger motif (Mott et al., 1996), is also important for Raf
activation. RBD-mediated relocalization enables interaction of the CRD with the farnesyl group on
Ras and with phosphatidylserine in the plasma membrane (Ghosh et al., 1996; Hekman et al., 2002).
Engagement of the CRD is essential for both relief of autoinhibition and the stable association of
Raf with the plasma membrane (Bondeva et al., 2002; Cutler et al., 1998; Roy et al., 1997).
Interaction with Ras and membrane phospholipids displaces 14-3-3 which allows for
dephosphorylation of inhibitory phosphorylation sites (McPherson et al., 1999; Rommel et al.,
1996), and promotes activating phosphorylation of the Raf kinase domain. Thus, de-repression and
activation of Raf requires its recruitment to the plasma membrane to enable interaction of the RBD
and CRD with Ras and membrane phospholipids.
Another key requirement for Raf activation is dimerization. Raf proteins can form
homodimers or heterodimers consisting of any combination of the Raf proteins, and these are
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mediated by side-to-side interactions between the kinase domains (Rajakulendran et al., 2009).
Conformational changes and phosphorylation of the negatively charged N-terminal regulatory
region of Rafs following membrane recruitment not only releases autoinhibition but also promotes
dimerization of Rafs (Baljuls et al., 2011; Cutler et al., 1998; Hu et al., 2013; Tran and Frost, 2003;
Tran et al., 2005). It is also thought that membrane recruitment by Ras binding promotes Raf
dimerization by increasing the local concentration of Raf proteins at the cell surface (Hibino et al.,
2009; Plowman et al., 2005; Terai and Matsuda, 2005; Tian et al., 2007). Dimerization acts to
stabilize each member of the dimer in the catalytically active “ON” conformation. This effect is
independent of the catalytic activity of the individual proteins in the dimer since Raf proteins that
are inactivated through mutation or pharmacologic inhibition can still promote the catalytic activity
of the Raf partner in the dimer (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al.,
2010; Wan et al., 2004). While all Raf proteins can form homodimers and can dimerize with any
other Raf protein, there does seem to be some preference in dimer formation since studies have
suggested that B-Raf/C-Raf heterodimers have the highest catalytic activity and predominate in
Ras-mediated signaling in many systems (Freeman et al., 2013b; Rushworth et al., 2006; Weber et
al., 2001).
Raf proteins can also dimerize with kinase suppressor of Ras (KSR) proteins, which share
significant structural and sequence homology with Rafs. Although they lack an RBD, KSRs
possess a carboxyl-terminal kinase domain and an amino-terminal domain that contains a CRD
followed by a region rich in serine/threonine residues (Therrien et al., 1995). In addition, the kinase
domain of KSRs is thought to be catalytically inactive. The kinase domain of KSRs can form sideto-side dimers with the Rafs analogous to those formed in Raf homodimers and heterodimers
(Brennan et al., 2011; Rajakulendran et al., 2009). Furthermore, as with Raf proteins, KSRs can
allosterically activate Raf dimerization partners by stabilizing them in the catalytic active “ON”
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confirmation (Hu et al., 2013). In addition to dimerizing the Rafs, KSR proteins also interact with
MEK and ERK, and act as a scaffolds to promote Raf-mediated ERK activation (Morrison, 2001).

Fig 1-14: Raf domain structure and protein interactions
(A) The Raf kinases can be divided into two functional domains: an amino-terminal regulatory
domain and a carboxyl-terminal kinase domain. They harbor three conserved regions (CRs): CR1,
which contains a Ras-binding domain (RBD) and a cysteine-rich domain (CRD); CR2, an area rich
in serine/threonine residues (S/T); and CR3, which contains the protein kinase domain. (B)
Numerous Raf-binding partners have been identified (adapted from (Terrell and Morrison, 2019)).
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1.3.7. Activation of MEK and ERK
The next step in the ERK activation cascade involves Raf-mediated activation of the dualspecificity MAPK/ERK kinases, MEK1 and MEK2. These kinases consist of a central catalytic
domain surrounded by short N-terminal and C-terminal sequences (Roskoski, 2012) (Fig 1-15).
The ~70 amino acid N-terminal sequence contains an autoinhibitory segment, a nuclear export
sequence, and an ERK binding site (Fig 1-15). Raf kinases have restricted substrate specificity and
phosphorylate MEK1 on S218 and S222 and MEK2 on S222 and S226 in the activation segment
of the catalytic domain (Barbosa et al., 2021; Roskoski, 2012). This phosphorylation induces a
conformational change that leads to activation of the kinases. MEK kinases also have very limited
substrate specificity and the only known physiological substrates are the ERK kinases. MEK1/2
phosphorylate threonine and tyrosine residues in a Thr-Glu-Tyr sequence in the activation segment
of ERK1 and ERK2. These phosphorylations, which occur on T-202 and Y-204 of ERK1 and T185
and Y-187 of ERK2, result in activation of ERK kinase activity.
In addition to phosphorylation of ERK, an important function of the MEKs kinases is as
cytoplasmic anchors for ERK. This interaction, which is mediated by the N-terminal ERK binding
site of MEK and the common docking (CD) domain in the C terminus of ERK (Chuderland and
Seger, 2005; Rubinfeld et al., 1999; Tanoue et al., 2000), is highly specific and sensitive to the
confirmation of ERK. In the absence of MEK, ERK localizes to the nucleus (Burack and Shaw,
2005); however, MEK contains a nuclear export sequence (NES) and is thought to both anchor
ERK in the cytoplasm and facilitate nuclear export of inactive ERK. In addition to localizing ERK
to the cytoplasm, this interaction also causes a conformational change that exposes the threonine
and tyrosine residues in the activation segment of ERK for phosphorylation by MEK.
Phosphorylation of ERK by MEK, in turn, induces conformational changes that lead to
enzymatic activation of ERK (Canagarajah et al., 1997; Shaul and Seger, 2007; Zhang et al., 1994).
This phosphorylation also leads to dissociation of the MEK/ERK complex and activated ERK
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translocates to the nucleus or remains localized in the cytoplasm bound to scaffold proteins
(Barbosa et al., 2021; Shaul and Seger, 2007). Following activation, ERKs directly phosphorylate
a large number of substrates in the cytoplasm and nucleus (Yoon and Seger, 2006). In addition,
ERK also phosphorylates and activates downstream kinases that further propagate the signal (Yoon
and Seger, 2006), with major substrates being the 90 kDa ribosomal S6 kinases RSKs (Sturgill et
al., 1988).

Fig 1-15: MEK kinases: structure and domains

Adapted from (Roskoski, 2012)
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1.3.8 ERK Pathway Regulation: Several mechanisms that regulate the specificity of the ERK
pathway have been identified (Fig 1-16), including
A. Duration and strength of signal: The first model proposed to explain signal specificity of
the ERK cascade involved the duration and strength of the signals transmitted by the
pathway (Marshall, 1995). In this model, ERK activity kinetics were studied in PC12 cells,
where a transient signal by EGF promoted cell proliferation, while an equally strong but
sustained signal by NGF resulted in differentiation (Nguyen et al., 1993). Interestingly,
artificial prolongation of ERK activity upon EGF stimulation changed the effect to
differentiation rather than proliferation (Traverse et al., 1994).
B. Scaffolds: Many of the functions of the ERK cascade are guided by scaffolds, which dictate
kinetics, localization, and components of the cascade. Scaffold proteins can also enhance
signaling fidelity by sequestering the kinases and insulating them from inappropriate
activation. In mammals, a large number of candidate scaffolds have been identified,
including KSR1, KSR2, MORG1 (also known as ED repeat domain-containing protein
83), IQGAP1, IQGAP3, SEF, FHKL1, GIT1, CAVIN4, paxillin, β-arrestins and the MP1
(also known as LAMTOR3)–p14–p18 complex (Casar and Crespo, 2016; Ogata et al.,
2014; Sheikh et al., 2008).
C. Subcellular localization: Restriction of components of the ERK pathway to specific
cellular compartments and dynamic changes in their localization after stimulation can also
regulate the specificity of the ERK pathway (Mor and Philips, 2006; Pouysségur et al.,
2002; Yoon and Seger, 2006). These processes direct signaling components such as Ras to
specific targets and organelles (e.g., Golgi), where they can stimulate a different function
and produce a different output (Matallanas et al., 2006). For example, forcing nuclear
localization of an ERK2-MEK1 chimera resulted in increased transcriptional activity
(Robinson et al., 1998), while forcing membrane association of ERKs resulted in attenuated
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transcriptional activity (Hochholdinger et al., 1999). In addition, restricting ERK2 activity
to the cytoplasm or the nucleus of myeloid leukemia cells provided protection from distinct
pro-apoptotic stimuli (serum starvation and the Bcr-Abl inhibitor STI571, respectively)
(Ajenjo et al., 2004).
D. Crosstalk and interplay with other signaling cascades: Although the multi-tiered ERK
cascades usually form linear pathways, crosstalk with other signaling cascades con modify
signaling output. These modifications usually affect the kinetic strength and localization of
the signals and are predominantly mediated by phosphorylation/dephosphorylation by
kinases and phosphatases that are not always part of ERK signaling pathways. In addition,
signals from other cascades often converge with ERK signals at downstream intermediates
to regulate transcription factors and alter the expression of target molecules (Raman and
Cobb, 2003).
E. Multiple isoforms in each tier of the cascade: Sequence similarity between the components
of the MEK and ERK tiers, and their identical substrate recognition, led to the initial belief
that they are functionally redundant. However, biochemical and genetic studies have made
it clear that differences in regulation between different isoforms do exist. Additionally,
ERK and MEK splice variants extend the number of targets, processes and outcomes
regulated by ERK cascade. For example, differences in MEK1 and MEK2 have been
reported. Upon EGF stimulation, C-Raf can activate both MEK1 and MEK2, but A-Raf
can only stimulate MEK2 in HeLa cells (Wu et al., 1996). This may affect MEK activity
as well as cell cycle progression, since reduced MEK1 activity, but not MEK2 activity,
results in G2/M arrest (Liu et al., 2004), and MEK isoforms have different effects on G1/S
phase transit (Ussar and Voss, 2004).
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Fig 1-16: Various Mechanism of regulating ERK pathway
Adapted from (Shaul and Seger, 2007)
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1.3.9 ERK Signaling Functions:
A. ERK signaling in cell proliferation: In proliferating cells, Ras-ERK signaling controls G1/S
phase progression, with loss of the three Ras genes or ERK1 or ERK2 in mouse embryonic
fibroblasts (MEFs) resulting in cell cycle arrest in G1 phase (Drosten et al., 2010; Voisin et al.,
2010). Expression of activated Ras is sufficient to drive quiescent cells into S phase (Stacey and
Kung, 1984). ERK can also modulate the G2/M transition to a lesser extent (Chambard et al., 2007;
Deschênes-Simard et al., 2014). In addition, hyperactivation of ERK can induce cell cycle exit and
senescence (Chambard et al., 2007; Deschênes-Simard et al., 2014).
B. ERK signaling in cell survival: Pharmacologic and genetic studies have pointed to a pro-survival
role of ERK signaling in response to serum and RTK activation (Berra et al., 1998). ERK-mediated
inhibition of apoptosis appears to be predominantly integrated by the intrinsic apoptosis pathway.
Several studies have identified ERK as an inhibitor of BIM, a BH3-only protein that can bind to all
anti-apoptotic proteins to promote cell death. One mechanism of functional inhibition of BIM
involves transcriptional suppression of the BIM encoding gene, BCL2L11, by ERK. ERK
phosphorylates the transcription activator, FOXO3A, leading to its nuclear exclusion and
proteasomal degradation in the cytoplasm (Yang et al., 2008).
C. ERK in cell growth: Cell size regulation in response to growth signals is important for both
proliferating and post-mitotic cells (Ginzberg et al., 2015). In proliferating cells, the G1/S transition
is often linked to the cell size checkpoint. The ERK cascade plays a secondary role in PI3K-AKTmTOR signaling, thereby regulating biosynthetic pathways. ERK enhances transcription of
ribosomal DNA (rDNA) by Pol I and of tRNA genes by Pol III (Bywater et al., 2013). ERK also
phosphorylates the transcription initiation factor for Pol I, which further stimulates Pol I
processivity (Zhao et al., 2003) leading to ribosome biogenesis and increased mRNA translation.
The oncoprotein Myc is another effector protein of the ERK cascade, whose expression enhances
protein synthesis and cell size in a cell cycle-independent manner (Iritani and Eisenman, 1999).

51

ERK can also affect mRNA translation by modulating mTORC1, a master regulator of cell size
and cell proliferation. Upon activation, mTORC1 induces multiple events resulting in protein
synthesis. Among the most prominent mTORC1 targets involved in mRNA translation are the
eIF4E-binding proteins, eIF4E-BP1 and eIF4E-BP2, S6 kinase (S6Ks), RPS6KB1 and RPSS6KB2
(Saxton and Sabatini, 2017).
D. ERK in cell motility: ERK signaling plays a crucial role in cell shape and motility during
processes like development and wound healing, and can facilitate disease processes, such as cancer
cell invasion. Activation of the Ras–ERK pathway can initiate cell motility in response to growth
factors or mechanotransduction (Tanimura and Takeda, 2017). ERK regulates cell migration via
phosphorylation of key components of the RHO family of GTPases (Fincham et al., 2000).
E. ERK signaling in differentiation and development: ERK is a master regulator of embryonic stem
cell (ESC) differentiation. Self-renewal of mouse ESCs (mESCs) is limited by FGF4 (fibroblast
growth factor 4)–ERK signaling, which drives differentiation from ground-state pluripotency
towards a more differentiated yet pluripotent state (Burdon et al., 1999; Kunath et al., 2007). ERK
also phosphorylates factors which are involved in maintenance of ground state pluripotency, and
destabilizes them (Ng and Surani, 2011). Moreover, ERK activates RSK (ribosomal S6 kinase) to
establish a negative feedback loop that promotes self-renewal of mESCs. In osteoblasts, ERK
signaling plays a role in differentiation downstream of FGF signaling, by phosphorylating the
transcriptional repressors ERF and RUNX2 (runt-related transcription factor 2). Dysregulation of
ERK signaling and of ERF and RUNX2 leads to malformations of cranial and facial bones (Lee et
al., 1997a; Twigg et al., 2013).
Overall, RAS-induced ERK signaling is important for regulation of cellular homeostasis
and organism development. Dysregulation of RAS-ERK signaling results in various human
pathologies, including cancer, developmental disorders, neurodegeneration, obesity, and ageing.
The complexity in the effects of ERK signaling is reflected in its broad repertoire of effector
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substrates. Depending on the cues and cell-context, ERK signaling can result in a variety of
different outcomes as discussed above in section 1.3.9.
1.4 PKC Intersection with Ras–ERK Signaling
It has long been recognized that members of the PKC family can activate the ERK pathway (Ahn
et al., 1992; Burry, 1998; Frey et al., 2000; Frey et al., 1997; Marquardt et al., 1994; Schönwasser
et al., 1998; Thomas et al., 1992; Ueda et al., 1996). Surprisingly, however, there has been
considerable confusion regarding the point of intersection between PKC signaling and the ERK
pathway, with several models proposed. The role of Ras in PKC–ERK crosstalk has been
especially controversial, with much of the confusion arising from the use of a dominant-negative
mutant of Ras in which amino acid 17 is changed to Asn (N17Ras). While this mutant, which is
thought to inhibit Ras activation by sequestering Ras-GEFs, blocks growth factor-induced ERK
activation (e.g., EGF (Marshall, 1995; McKay and Morrison, 2007; Morrison and Cutler, 1997)),
it fails to inhibit ERK activation by PKC in multiple cell types, pointing to Ras-independent
activation of ERK pathway components (Ueda et al., 1996). Consistent with this conclusion, a highprofile study by Rapp and colleagues (Kolch et al., 1993) reported that PKCα can directly
phosphorylate and activate c-Raf, and that PKCα-mediated phosphorylation at Ser499 and Ser259
is required for c-Raf activation by the kinase. Subsequent studies challenged these findings. An
equally high-profile study (Marais et al., 1998) showed that microinjection of Ras-neutralizing
monoclonal antibody or expression of a Raf mutant that cannot bind GTP-bound Ras (R89LRaf-1)
abrogated ERK activation by PKC in COS cells, pointing to an essential role for Ras in PKCmediated activation of ERK. Parker and colleagues (Schönwasser et al., 1998) showed that
classical, novel, and atypical PKCs can activate MEK and ERK and that classical and novel, but
not atypical PKCs, activate c-Raf via a mechanism that does not require phosphorylation at Ser
residues 259 or 499. The Black laboratory previously demonstrated that PKC/PKCα promotes GTP
loading of Ras, c-Raf activation, and ERK phosphorylation in intestinal epithelial cells, although
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the requirement for Ras activity in activation of ERK was not assessed (Clark et al., 2004). Notably,
Wen-Sheng (Wen-Sheng, 2006) reported that PKCα triggers Ras- and Raf-independent MEK/ERK
activation in human hepatoma cells and Monick et al. argued that PKCζ can activate MEK by direct
phosphorylation (Monick et al., 2000), although direct activation of MEK by PKCs is controversial
(Schönwasser et al., 1998). Crosstalk with Raf regulatory proteins has also been implicated in PKCinduced activation of ERK. Phosphorylation of Raf kinase inhibitory protein (RKIP) by classical
and atypical PKCs at Ser153 was shown to promote dissociation of RKIP from c-Raf, thereby
activating the ERK pathway (Corbit et al., 2003).
In conclusion, while it is clear that PKC/ERK signaling crosstalk is involved in regulating
important cellular functions, the requirement for ERK signaling components such as Ras and Raf
remains unclear and may be context-dependent.
1.4.1. PKCs and RasGRPs
Another point of intersection between PKC signaling and the ERK pathway is upstream of
Ras at the level of Ras GEFs. Members of the RasGRP family have a Cl domain that is analogous
to the C1 domains found in PKCs and are able to bind DAG and phorbol esters. They also have
atypical EF hand motifs that may bind Ca2+. Thus, signals that generate DAG as a result of
activation of phospholipase C recruit RasGRPs through their C1 domain; however, this recruitment
is not sufficient to activate RasGRP1 or RasGRP3. RasGRP1 and RasGRP3 are phosphorylated by
PKC on T184 and T133, respectively, and this phosphorylation is required for their full activation
(Aiba et al., 2004; Roose et al., 2005; Zheng et al., 2005). While overexpression studies have
implicated PKCδ and PKCθ as RasGRP3 kinases (Brodie et al., 2004; Zheng et al., 2005),
phosphorylation of T133 on RasGRP3 and RasGRP3-dependent activation of Ras/ERK following
B cell activation was inhibited by Gö6976, indicating that cPKC(s) are physiological kinases for
this GEF (Aiba et al., 2004; Zheng et al., 2005). Similarly, cPKCs appear to mediate
phosphorylation of RasGRP1 since Gö6976 also inhibits its phosphorylation on Thr184 and blocks
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RasGRP1-mediated activation of ERK in activated T cells (Zheng et al., 2005). Interestingly, the
C1 domain of RasGRP2 does not bind to DAG (Irie et al., 2004) and RasGRP2 fails to translocate
to membranes in vivo in response to DAG generation.
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1.5 Objectives of the Study:
Previous studies from our laboratory have shown that PKCα has anti-proliferative and
antitumor effects in the intestinal epithelium and the endometrium (Frey et al., 2000; Frey et al.,
1997; Hsu et al., 2018; Pysz et al., 2009; Saxon et al., 1994). We have demonstrated that PKCα
signaling potently induces G1→S phase cell cycle arrest in these cells, in association with
downregulation of mitogenic proteins such as D-type cyclins and Id1 and upregulation of the cyclin
dependent kinase inhibitors p21 and p27 (Clark et al., 2004; Frey et al., 1997; Hao et al., 2011;
Hizli et al., 2006). The cell cycle-specific effects of PKCα are also associated with activation of the
MEK–ERK pathway (Clark et al., 2004). Since the MEK–ERK pathway is a well-recognized proproliferative signaling pathway in normal intestinal cells and in colon cancer, the objective of this
study is to define the novel PKCα-induced growth suppressive MEK–ERK signaling cascade
identified in normal intestinal epithelial cells.
The specific goals of this study were to reveal the mechanistic basis of this novel PKCαinduced growth inhibitory signaling pathway by (a) determining the point at which PKCα intersects
the canonical RAS–RAF–MEK–ERK cascade, (b) identifying the signaling intermediates that link
PKCα to the ERK pathway, and (c) comparing its effects with those of a pro-proliferative MEK–
ERK stimulus such as EGF. In the initial part of the study, a variety of experimental techniques is
used to validate the requirement for each component of the canonical ERK pathway. Subsequent
studies explore crosstalk between these pathways and establish the generality of observed effects.
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MATERIALS AND METHODS
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2.1 Cell Culture: IEC-18 (ATCC CRL-1589) and IEC-6 (ATTC CRL-1592) rat intestinal crypt-like
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5%
fetal bovine serum (FBS), 4 mM L-glutamine, 1 mM sodium pyruvate, and 5 μg/ml insulin at 37°C.
For serum starvation, IEC-18 cells were cultured for 24 h in the same medium except containing
0.5% FBS. N-Ras-/-H-Ras-/-; K-Rasf/f mouse embryonic stem cells (Rasless cells mESCs) were
grown on mouse embryonic fibroblast (MEF) feeder cells or weaned off and grown on 0.1% Gelatin
(Millipore Sigma) in DMEM supplemented with 15% FBS, 1000 U/ml LIF (Millipore Sigma), 1%
glutamax, 0.1 mM non-essential amino acids, 1% penicillin/streptomycin and 55 mM βmercaptoethanol (Mayor-Ruiz et al., 2018). MEFs were obtained from 14-17 old embryos and
cultured in DMEM supplemented with 10% FBS and 0.1 mM β-mercaptoethanol. For generation
of feeder cells, MEFs were gamma irradiated with 5000 Rads.
2.2 Stem Cell Culturing: Stem cells were maintained at a low confluency to avoid differentiation. In
a 10 well plate, 3x106 feeder cells (MEFs) were grown to confluency, followed by gamma
irradiation to growth inactivate. Irradiated feeder cells were checked for growth by maintenance at
37C overnight. 2-3x106 stem cells (30,000-50,000 mESCs/cm2) were seeded on a layer of feeder
cells. Growth medium was changed every day and cells were split every alternate day to avoid
differentiation and pH changes. After two passages on feeder cells, cells were grown on gelatincoated plates (at the same density) and weaned off feeder cells. For experiments, 0.5x106 cells were
plated in 6 well plates and 1 μM 4-Hydroxytamoxifen was added in fresh medium every day for
the next 7 days. Cells were split every second or third day depending on confluency (50-70% is
optimal).
2.3 Drug Treatments and Reagents: PKCα was activated by treatment with 100 nM phorbol 12myristate 13-acetate (PMA) (Sigma) dissolved in ethanol or 20 μg/ml 1,2-sn-dioctanoylglycerol
(DiC8) (Cayman chemicals) dissolved in acetontrile. EGF was dissolved in phosphate-buffered
saline (PBS) and was added to cells at 50-100 ng/ml for the indicated times. For inhibitor
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treatments, cells were pre-treated with the indicated concentrations of bisindolylmaleimide I (Bim)
(Calbiochem), Gö6976 (Calbiochem), SCH772984 (SelleckChem), LY3009120 (Med Chem
Bioexpress), PD0325901 (SelleckChem) or Salirasib (SelleckChem) dissolved in DMSO.
Inhibitors were added 1 h before PKCα agonist treatment, unless otherwise stated. The relevant
vehicle was added to controls and the final concentrations of solvents was <0.2%. 4Hydroxytamoxifen (4-OH-T, Sigma) was dissolved in ethanol.
2.4 Antibodies: Primary and Secondary antibodies for Western blots were (Table 2):
Antibody

Source

From

Catalog #

Dilutions

Actin

Rabbit

Sigma

A2066

1:20,000 in 5%
Milk/BSA
overnight at 4˚C

A-Raf

Rabbit

Cell Signaling

75804S

Technology

1:1000 in 5%
BSA overnight
at 4˚C

B-Raf

Rabbit

Cell Signaling

14814S

Technology

1:1000 in 5%
BSA overnight
at 4˚C

C-Raf

Mouse

BD pharma

610151

1:2000 in 5%
Milk overnight
at 4˚C

C-Raf Ser 259

Rabbit

Cell Signaling
Technology

9421

1:1000 in 5%
BSA overnight
at 4˚C
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C-Raf Ser 338

Rabbit

Cell Signaling

9427

Technology

1:1000 in 5%
BSA overnight
at 4˚C

Cyclin D1

Rabbit

Cell Signaling

2978

Technology

1:1000 in 5%
BSA overnight
at 4˚C

Gapdh

Rabbit

Cell Signaling

5174

Technology

1:2000 in 5%
BSA overnight
at 4˚C

H-Ras

Rabbit

Abclonal

A19619

1:1000 in 3%
BSA overnight
at 4˚C

Hsp73/HSC70

Mouse

Enzo

ADI-SPA-815

1:1000 in 5%
BSA overnight
at 4˚C

Id1

Rabbit

Biocheck

BCH-1/195-14-50 1:2000 in 5%
BSA overnight
at 4˚C

KSR 1

Rabbit

Abcam

ab68483

1:1000 in 5%
BSA overnight
at 4˚C

KSR 2

Rabbit

Abnova

H00283455-M08

1:1000 in 5%
BSA overnight
at 4˚C
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p21

Mouse

BD Pharma

556430

1:500 in 5%
Milk overnight
at 4˚C

p21

Mouse

Novus

NBP2-29463

1:500 in 5%
Milk overnight
at 4˚C

pan-Ras

Rabbit

Cell Signaling

3339S

Technology

1:1000 in 5%
BSA overnight
at 4˚C

pERK

Mouse

Cell Signaling

9106

Technology

1:2000 in 5%
Milk overnight
at 4˚C

PKCα

Rabbit

Abcam

ab32376, ab221611 1:20,000 in 5%
BSA overnight
at 4˚C

pMEK

Rabbit

Cell Signaling

9121

Technology

1:1000 in 5%
BSA overnight
at 4˚C

pRSK (S380)

Rabbit

Cell Signaling

9341

Technology

1:1000 in 5%
BSA overnight
at 4˚C

pRSK (S380)

Rabbit

Millipore

04-418

1:1000 in 5%
BSA overnight
at 4˚C
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RasGRP1

Rabbit (polyclonal) Abclonal

A10495

1:1000 in 3%
BSA overnight
at 4˚C

RasGrp3

Mouse

Santa Cruz

sc-271068

1:1000 in 5%
Milk overnight
at 4˚C

Total ERK

Rabbit

Cell Signaling

9102

Technology

1:2000 in 5%
BSA overnight
at 4˚C

Total MEK

Rabbit

Cell Signaling

9122

Technology

1:1000 in 5%
BSA overnight
at 4˚C

Table 2: List of Primary Antibodies
Secondary antibodies were horseradish peroxidase-conjugated goat anti-rabbit IgG (Millipore, and
horseradish peroxidase conjugated goat anti-mouse IgG (Bio-Rad) (Table 3).
Goat anti-Rabbit

Millipore

AP132P

IgG-HRP

1:1000 in 5%
Milk 2 hr at
RT

anti-mouse IgG-

Biorad

170-6516

HRP

1:1000 in 5%
Milk 2 hr at
RT

Table 3: List of Secondary Antibodies
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2.5 Western Blotting: Cells were washed twice with ice cold PBS, followed by lysis in 1% SDS, 10
mM Tris-HCl, pH 7.4. Lysates were centrifuged at 13,000 rpm for 15 min, DNA was sheared by
passage through a gauge 27 needle, and protein concentration was determined using the BCA Assay
Kit (Pierce). Equal amounts of protein were subjected to SDS PAGE and transferred to
nitrocellulose membranes. Membranes were stained with 0.1% fast green (Sigma) to confirm equal
loading and even transfer. Membranes were blocked with 5% milk and probed with primary
antibodies overnight at 4C on a rocker using concentrations indicated in Table 2. All primary
antibodies were prepared in BSA or milk as indicated by the manufacturer and experience in the
laboratory. Following washing (3 x 10 min in TBS-T), membranes were incubated with anti-rabbit
IgG or anti-mouse IgG (1:1000) for 2 hr at room temperature (RT). Signal detection on washed
membranes was performed using SuperSignal West (Pierce). Signal intensity was quantified from
scanned films using ImageJ Software (NIH).
2.6 siRNA Transfection: 1.5 x 105 IEC-18 or IEC-6 cells were transfected with 100 pmol of gene
specific siRNA (Dharmacon or Ambion) or with non-targeting siRNA (Dharmacon) using
Lipofectamine RNAimax reagent (Invitrogen). ON-TARGET plus SMARTpool siRNAs are a pool
of four siRNAs designed and modified to increase specificity and reduce off-target effects. Analysis
was performed 48 h after transfection, unless stated otherwise.
siRNA sequences were as follows (Table 4):
siRNA

Catalog

ON-TARGETplus Non-

D-001810-01-

From

Sequences (5'->3')

Dharmacon
targeting siRNA #1

05
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ON-TARGETplus Rat A-Raf
L-088540-02(64363) SMARTpool siRNA,

Dharmacon
0005

5 nmol

ON-TARGETplus Rat B-Raf
L-094802-02(114486) SMARTpool

Dharmacon
0005

siRNA, 5 nmol

ON-TARGETplus Rat C-Raf
L-087699-02(24703) SMARTpool siRNA,

Dharmacon
0005

5 nmol

ON-TARGETplus Rat H-Ras
L-084782-01(293621) SMARTpool siRNA,

Dharmacon
0005

5 nmol

ON-TARGETplus Rat KSR1
L-085072-02(360573) SMARTpool

Dharmacon
0005

siRNA, 5 nmol

ON-TARGETplus Rat
L-100584-02RasGRP1 (29434)

Dharmacon
0005

SMARTpool siRNA, 5 nmol
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ON-TARGETplus Rat
L-098911-02RasGRP3 (313874)

Dharmacon
0005

SMARTpool siRNA, 5 nmol

Silencer select pre-designed
4392420

Ambion

GGAAGUAGCUAGUCAACUATT

4390771

Ambion

CAAGCACGCUUUCGAAAUATT

4390771

Ambion

GCUUUUGAAUUAGUAUCCATT

Rasgrp3 siRNA, 5 nmol

Silencer select pre-designed
SOS1 siRNA, 5 nmol

Silencer select pre-designed
SOS2 siRNA, 5 nmol

Table 4: siRNA Sequences

2.7 Flow Cytometry: Sub-confluent IEC-18 cells were briefly washed with PBS and treated with
trypsin (Gibco) to obtain single-cell suspensions. 9 x 105 cells were fixed with 70% ethanol and
stained overnight at 4C with Telford’s reagent [90 mM EDTA, 0.1% (v/v) Triton X-100, 50 μg/ml
propidium iodide in PBS]. DNA content of cells was determined by flow cytometric analysis in the
Flow Cytometry Research Facility at UNMC. Cell cycle analysis was performed using FlowJo
(FloJo LLC) and ModFit software.
2.8 Immunoprecipitation: IEC-18 cells treated with PMA or vehicle for 10 min were rinsed twice
with ice-cold PBS, and harvested in ice-cold PBS using a cell scraper, centrifuged at 1000 x g for
5 min at 4C, and lysed for 15-30 min on ice in immunoprecipitation buffer [1% NP-40/Ipegal CA-
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630, 137 mM NaCl, 20 mM Tris-Cl, pH 8.0, 0.5 mM EDTA with freshly added Protease Inhibitor
Cocktail and Phosphatase Inhibitor Cocktails I and II (Sigma)]. Lysates were centrifuged at 13,000
rpm for 15 min, and protein concentration of the supernatants was quantified as above. 500-1000
μg of protein was incubated with specific antibody (diluted as recommended by the manufacturer)
or isotype-matched IgG (control), and rocked overnight at 4C. Antibody-protein complexes were
collected using A/G agarose beads (Santa Cruz) and subjected to Western Blotting.
2.9 Phos-tag Gel Analysis: For experiments involving λ-phosphatase treatment, cells were lysed in
immunoprecipitation buffer or in immunoprecipitation buffer lacking phosphatase inhibitors and
lysates were cleared by centrifugation at 1000 x g. Supernatants lacking phosphatase inhibitors
were adjusted to 1 mM MnCl2, and 800 units of λ-phosphatase (P0753, New England Biolabs) were
added. Supernatants were incubated for 30 min at 30C before their protein concentration was
quantified and an equal volume of 2x SDS sample buffer was added. Samples were subjected to
SDS-PAGE/Western blotting using a 6% acrylamide resolving gel containing 20 μg Phos-tag
reagent (Wako Pure Chemical Industries, AAL-107) in the presence of 0.1 mmol/L MnCl2 (as
recommended by the Phos-tag manufacturer). To maximize protein separation, electrophoresis was
performed at 60-90 V. Following electrophoresis, gels were equilibrated in transfer buffer
containing 10 mM EDTA (2 x 10 min). The gels were then soaked in regular transfer buffer for
another 10 min followed by Western blotting.
2.10 Immunohistochemistry: Deparaffinized sections were rehydrated with ddH2O water for 5 min.
For antigen retrieval, slides were heated in preheated DAKO target retrieval solution (1:10 to make
1x solution, pH 6.0-6.2), for 30-50 min at 90C, followed by cooling for 20 min. Sections were
washed twice for 5 min with ddH2O, immersed in 3% H2O2 for 10 min, and washed twice for 5 min
with ddH2O. For blocking, sections were first washed with TBST for 5 min followed by blocking
in 5% normal goat serum in TBS-T for 1 h at room temperature. Sections were incubated with
primary anti-pERK antibody (Cell Signaling Technology antibody diluted 1:400) overnight at 4C
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in a humidified chamber. A few drops of CST signalstain boost anti-rabbit IgG polymer were
applied to sections for 30 min. Sections were washed with TBS-T 3 times for 5 min, before
incubation with DAKO DAB for 1-10 min. Excess DAB was removed by rinsing sections in water
for 3 min. Sections were counterstained for 1-2 min in hematoxylin, differentiated in 1% acid
alcohol, and washed in tap water for 3 min. Sections were then dehydrated in graded alcohols and
cleared in Xylene before mounting with coverslips.
2.11 Software and Statistical Analysis: Cell cycle analysis of flow cytometric data was performed
using FlowJo (FloJo LLC) and Modfit (Verity Software) Software. Densitometric analysis of
scanned Western blot data was performed with Image J Software (NIH) using multiple exposures
of each blot. Contrast and brightness of scanned blots was adjusted using GMU Image
Manipulation Program (GIMP), Adobe Photoshop, or Microsoft PowerPoint Software. All
adjustments to contrast and brightness were made equally across the entire blot and no individual
lanes were treated differently than the rest of the blot. In some figures, dotted lines indicate where
lanes have been rearranged for clarity: in all cases lanes in each panel are from the same exposure
of a single blot. Graphs were generated using Microsoft Excel Software and figures were assembled
and annotated in Microsoft PowerPoint Software. Statistical analysis was performed using
Microsoft Excel software. Statistical significance of differences was assessed using one-sided or
two-sided Student’s t tests (as indicated in figure legends), with p values ≤ 0.05 considered
significant.
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3.1 Summary of Previous Findings:
Our previous studies support a role for PKCα in maintenance of cellular homeostasis in the
continuously self-renewing intestinal epithelium. Using in vivo and in vitro approaches, we
demonstrated that (i) PKCα is diffusely distributed in the cytosol and inactive in proliferating
intestinal crypt cells, (ii) membrane translocation/activation of the enzyme in the mid- to-upper
crypt region coincides with cell growth arrest, and (iii) membrane association of the enzyme is
maintained along the length of the villus/post-mitotic compartment [(Frey et al., 2000; Frey et al.,
1997; Hao et al., 2011; Saxon et al., 1994; Verstovsek et al., 1998), Fig 3-A)]. In vitro studies using
IEC-18 intestinal crypt-like cells demonstrated that activation of PKCα triggers G1→S phase arrest
and cell cycle withdrawal into G0 [(Frey et al., 2000), Fig 3-B)]. PKCα-induced cell cycle arrest
requires sustained PKCα and MEK/ERK activity (Clark et al., 2004), and is associated with
increased expression of the CDK inhibitors p21 and p27 and rapid downregulation of D-type
cyclins. These effects result in inhibition of the activity of all major G1/S cyclin/CDK complexes
(Frey et al., 2000). Downregulation of cyclin D1 occurs via two mechanisms, (i) translational
inhibition by PP2A-mediated hypophosphorylation/activation of the translational repressor 4EBP1, and (ii) inhibition of cyclin D1 transcription (Guan et al., 2007; Hizli et al., 2006; Pysz et al.,
2014; Pysz et al., 2009). In intestinal cells, PKCα also suppresses the expression of mitogenic Id1
via an ERK-dependent mechanism (Hao et al., 2011), a function that has been noted in other
systems (Akakura et al., 2010; Hill et al., 2014).
The canonical ERK pathway, Ras–Raf–MEK–
ERK, involves a cascade of multiple components. In this study, we characterize the ERK pathway
components required by PKCα to induce G1→S phase cycle arrest. PKCα activation is achieved
using pharmacological agonists: the phorbol ester, PMA, and the short chain DAG, DiC 8. PKCαmediated effects on the cell cycle are evaluated by flow cytometry and using the downstream targets
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cyclin D1, Id1, and p21 as readouts. Crosstalk between PKCα and the MEK-ERK cascade is also

Figure 3-A: PKCα expression and subcellular localization in intestinal epithelial cells in situ
investigated at a mechanistic level.
The left panel shows immunohistochemical localization of PKCα in the mouse small intestinal
epithelium [from (Hao et al., 2011)]. PKCα is diffusely distributed throughout the cytosol in
actively proliferating crypt cells (thick arrow). Proliferation is detected by staining for the
proliferation marker, Ki67 (right panel, adapted from (Li et al., 2007). At the crypt/villus junction,
indicated by the dashed line in both panels, PKCα is cleared from the cytosol and associates with
the plasma membrane, in the classical indication of PKCα activation. Thus, PKCα activation
coincides with cell growth arrest at the crypt/villus junction. Note that post-mitotic Paneth cells at
the base of the crypt also stain for PKCα at the plasma membrane.

70

Figure 3-B: Activation of PKCα in intestinal epithelial cells triggers G1→S phase arrest and
cell cycle withdrawal into G0

IEC-18 non-transformed rat intestinal crypt-like cells were treated with PMA for 3 h, 6 h and 12 h.
Samples were then subjected to flow cytometric analysis to determine cell cycle distribution. The
percentage of cells in G1, S and G2/M phase is shown with the DNA histograms. (Adapted from
(Frey et al., 1997).
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3.2 Activation of PKCα by PMA induces ERK-dependent Anti-proliferative Signaling in Intestinal
Epithelial Cells:
We have previously reported that pharmacological activation of PKCα induces cell cycle arrest in
intestinal epithelial cells (IEC-18 non-transformed intestinal crypt cells), in association with
activation of the ERK signaling pathway, as determined using phospho-ERK-specific antibody and
Western blot analysis [(Clark et al., 2004) and (Fig 3-1)]. To confirm the requirement for ERK in
the anti-proliferative activity of PKCα, we examined the ability of the ATP-competitive ERK
inhibitor, SCH772984, to inhibit PMA/PKCα-induced cell cycle arrest and modulation of the
downstream targets cyclin D1, Id1 and p21. The efficiency of SCH772984-mediated inhibition of
ERK in IEC-18 cells was confirmed using phosphorylation of the ERK substrate, RSK, as a
readout, assessed by Western blotting using phospho-RSK-specific antibody (Fig 3-1).
For analysis of cell cycle-specific effects, IEC-18 cells were pre-treated with SCH772984
for 1 h, followed by addition of PMA for 6 h, and samples were subjected to flow cytometric
analysis. Activation of PKCα led to G1→S phase arrest, as shown by a 50% increase in the
percentage of cells in G1-phase and a >70% reduction in the percentage of cells in S-phase (Fig 32, compare flow histograms 1 and 2). Consistent with a role for pro-proliferative ERK signaling in
intestinal epithelial cells, ERK inhibition with SCH772984 led to a modest decrease (~30%) in
cells in S-phase (Fig 3-2, compare flow histograms 1 and 3). However, the ERK inhibitor also
abrogated PMA/PKCα-induced G1→S arrest in these cells (Fig 3-2, flow histogram 4). Consistent
with flow cytometric data, IEC-18 cells treated with PMA showed downregulation of cyclin D1
and Id1 and increased levels of p21. Notably, SCH772984 blocked the effects of PKC/PKCα on
readout proteins (Fig 3-2), confirming that ERK activity is required by PKCα anti-proliferative
function in intestinal cells.
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Fig 3-1: The selective ERK inhibitor, SCH772984, blocks PMA induced effects on ERK, cyclin
D1, Id1 and p21
IEC-18 cells were pretreated with vehicle or 1 μM SCH772984 for 1 h, followed by treatment for
2 h with 100 nM PMA. Samples were then subjected to Western blotting for analysis of the
expression of pERK, pRSK, cyclin D1, p21 and Id1. Actin is used as a loading control. Data are
representative of >3 independent experiments.
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Fig 3-2: The selective ERK inhibitor, SCH772984, blocks PMA induced G1→S phase arrest
IEC-18 cells were pretreated with vehicle or 1μM SCH772984 for 1 h, followed by treatment with
100 nM PMA for 6 h. Samples were then subjected to cell cycle analysis by flow cytometric
measurement of DNA content. The percentage of cells in G1, S and G2/M phase is shown below
the DNA histograms. Data are representative of 2 independent experiments.
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To further understand PKCα-triggered anti-proliferative ERK signaling, we compared
PMA/PKCα-induced ERK activation with ERK activation induced by a known growth stimulatory
factor, epidermal growth factor (EGF). To avoid confounding effects of serum growth factors in
the medium, these experiments were performed under serum-starved conditions (0.5% serum as
opposed to 5% serum in regular medium). EGF and PMA treatments led to comparable activation
of ERK, indicated by an increase in ERK phosphorylation (Fig 3-3(i)), although the duration of
pERK signal induced by these stimuli is different, as previously reported by our group [(Clark et
al., 2004), and (Fig 3-3(ii)]. While EGF-induced ERK activation is sustained for 15-30 min,
PMA/PKCα-induced ERK activity remains high for more than 2 h.
Next, we tested the requirement for PKC activity in the effects of PMA and EGF on ERK
using the general PKC inhibitor, BIM I, or the ‘classical’ PKC-selective inhibitor, Gö6976. As
anticipated, EGF-induced ERK activation was unaffected by PKC inhibitors. In contrast, BIM I
and Gö6976 led to a 3-4-fold decrease in the ability of PMA to increase ERK phosphorylation (Fig
3-4). Since, PKCα is the only conventional PKC isozyme expressed in IEC-18 cells, these data
point to a predominant role for PKCα in the effects of PMA on ERK activity in IEC-18 cells. These
data also confirm our previous finding that PKCα activates anti-proliferative ERK signaling that is
distinct from the canonical pro-proliferative ERK axis induced by growth factors (Clark et al.,
2004).
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Fig 3-3: PMA induces PKCα-dependent prolonged ERK activation in IEC-18 cells

Fig 3-3(i): PMA-induced ERK activation is comparable with EGF-induced ERK activation
IEC-18 cells were cultured in either 5% complete medium (normal serum) or 0.5% serum (serumstarved) for 24 h, followed by treatment with 100 nM PMA or 50 ng/ml EGF for 10 min, and
samples were analyzed for phosphorylation of ERK by Western blotting. Data are representative
of at least 3 independent experiments.

Fig 3-3(ii): Comparison of ERK signal strength and duration induced by PMA and EGF
IEC-18 cells were serum-starved overnight, followed by a time course treatment with 100 nM PMA
or 100 ng/ml EGF. Harvested cells were subjected to Western blot analysis for the indicated
proteins. Data are representative of at least 3 independent experiments.

77

Fig 3-4:The PKCα selective inhibitor Gö6976 inhibits PMA-induced ERK activation
Serum-starved IEC-18 cells were pretreated for 1 h with 4 μM Gö6976 (PKCα selective in IEC-18
cells) or 5 μM BIM I (general PKC inhibitor), before treatment with vehicle, 100 ng/ml EGF or
100 nM PMA for 10 min. Numbers below the blots show the relative band intensity (normalized
to β-actin and control) for the different proteins, and the increase in relative band intensity induced
by EGF and PMA over that measured for the corresponding samples not treated with EGF/PMA.
All data are representative of at least 3 independent experiments.
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3.3 PKCα-induced Growth Suppressive ERK Signaling Requires MEK Activity:
The canonical ERK signaling cascade involves sequential activation of Ras, Raf, and MEK which
activates ERK by phosphorylation (Canagarajah et al., 1997; Fincham et al., 2000; Howe et al.,
1992; Lavoie et al., 2020; McKay and Morrison, 2007; Rubinfeld and Seger, 2005; Zhang et al.,
1994). Subsequent experiments, therefore, investigated the point of intersection between PKCα
signaling and the ERK pathway, and the requirement for canonical ERK pathway components in
the anti-proliferative effects of PKCα activation. As seen with ERK inhibition by SCH772984,
blockade of ERK activation with the MEK inhibitor, U0126, caused a 30-35% reduction in S-Phase
cells (Fig 3-5, compare flow histograms 1 and 3). Consistent with our previous findings (Clark et
al., 2004), U0126 also blocked the ability of PMA to induce G1→S-phase arrest (Fig 3-5). Both
U0126 and the second generation MEK inhibitor, PD0325901, also inhibited the ability of PMA to
activate ERK and induce downregulation of cyclin D1 and Id1 and upregulation of p21 [Fig 3-6
and data not shown; (Clark et al., 2004)], confirming that PKCα-induced growth suppressive ERK
signaling is dependent on MEK activity.

79

Flow histogram # 1

2

3

4

Fig 3-5: MEK inhibition blocks PMA-induced G1→S phase arrest
IEC-18 cells were pretreated with vehicle or 10 μM U0126 for 1 h, followed by treatment with 100
nM PMA for 6 h. Samples were then subjected to cell cycle analysis by flow cytometric
measurement of DNA content. The percentage of cells in G1, S and G2/M phase is shown below
the DNA histograms. Note that the data are part of the same experiment shown in Fig. 3-4, vehicle
and PMA-treated control panels on the left are therefore the same in both figures.
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Fig 3-6: MEK inhibition inhibits PMA-induced effects on readout proteins
IEC-18 cells were pretreated with vehicle or 10 μM PD0325901 for 1 h, followed by treatment with
100 nM PMA for 2 h. Samples were then subjected to Western blotting analysis for the expression
of pERK, cyclin D1, p21 and Id1. Actin is used as a loading control. Data are representative of 3
independent experiments.

81

3.4 The growth suppressive PKCα/ERK signaling pathway requires Raf activity:
To investigate if growth suppressive ERK signaling requires Raf activity, we used the pan-Raf
inhibitor LY3009120, an ATP-competitive inhibitor that blocks all Raf isoforms with the same
affinity and binds tightly to protomers of Raf proteins (Brummer and McInnes, 2020; Peng et al.,
2015). As shown in Figs 3-7 and 3-8, inhibition of Raf activity by LY3009120 abrogated
PMA/PKCα-induced G1→S phase arrest as well as alterations in expression of cyclin D1, Id1, and
p21.
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Fig 3-7: The pan-Raf inhibitor, LY3009120, prevents PMA/PKCα-induced G1→S arrest
IEC-18 cells were pretreated with 3 μM LY3009120 for 1 h, followed by 100 nM PMA for 6 h and
cell cycle distribution was analyzed by flow cytometry. Data are representative of 3 independent
experiments.
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Fig 3-8: Pan-Raf inhibition blocks PMA-induced effects on readout proteins in a dosedependent manner
IEC-18 cells were pre-treated with either vehicle (EtOH) or the pan-Raf inhibitor, LY3009120, for
1 h, followed by 100 nM PMA treatment for 2 h, and samples were analyzed by Western blotting
to reveal effects on readout proteins. Data are representative of >3 independent experiments.
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PMA treatment also led to a mobility shift in C-Raf as observed on SDS-PAGE, suggestive
of a change in its phosphorylation. Changes in C-Raf phosphorylation were, therefore, analyzed
using phospho-specific antibodies. This analysis revealed an increase in activating phosphorylation
of C-Raf at S338 and a reduction in its inhibitory phosphorylation at S259 (Fig 3-9). Importantly,
the mobility changes in total C-Raf as well as phospho-CRaf (S338 and S259) were blocked by the
PKCα selective inhibitor Gö6976 (Fig 3-10 (i), (ii)), confirming that PMA-induced Raf activation
is predominantly mediated by PKCα in IEC-18 cells. Together, these findings indicate that PKCαmediated growth inhibitory ERK signaling also requires Raf activity.

NS

Fig 3-9: PMA/PKCα treatment increases activating phosphorylation and decreases inhibitory
phosphorylation on C-Raf
IEC-18 cells were treated with vehicle or 100 nM PMA for the specified times and samples were
analyzed by Western blotting (Note: lower band in S259 blot (arrow) is non-specific as indicated
by Cell Signaling Technology). Data are representative of 2 independent experiments.
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Fig 3-10: The PKCα selective inhibitor Gö6976 blocks the mobility shift of C-Raf
IEC-18 cells were pretreated 4 μM Gö6976 for 1 h prior to addition of PMA for 10 min (i). (ii)
same as (i), except samples were also treated with EGF for 10 min. Samples were analyzed by
Western blotting, for indicated proteins. Data are representative of 2 independent experiments.
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There are three Raf isoforms in mammalian cells, A-Raf, B-Raf and C-Raf, that function
as homo- and/or heterodimers (Freeman et al., 2013a; Freeman et al., 2013b) .To investigate the
possibility that specific Raf isoforms or heterodimers mediate anti-proliferative ERK activation by
PKC agonists, siRNA knockdown experiments were performed. Individual knockdown of A-Raf,
B-Raf or C-Raf did not affect the ability of PMA to activate ERK and downregulate the downstream
targets cyclin D1 and Id1 or upregulate p21 (Fig 3-11), excluding a requirement for a specific Raf
isoform or homodimer for the effect. Interestingly, simultaneous knockdown of all possible Raf
pairs, effectively leaving the cells with only A-Raf, B-Raf or C-Raf, also failed to prevent the
effects of PMA treatment on cyclin D1, Id1 or p21 (Fig 3-11). Together, the data point to (a)
redundancy in the ability of Raf isoforms to mediate growth suppressive ERK activation, and (b)
the ability of Raf homodimers to mediate PKCα-induced growth suppressive signaling.
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Fig 3-11: siRNA knockdown of Rafs, individually or in combination, does not affect PMAinduced ERK activation or modulation of readout proteins
IEC-18 cells were transfected with either non-targeting siRNA (NT) or siRNA specific to Raf
isoforms for 48 h, followed by treatment with 100 nM PMA for 2 h. Samples were then subjected
to Western blotting to assess the expression of indicated proteins. The data are from single
immunoblots; the vertical lines in the cyclin D1 blot (left panel) indicate rearrangement of the blot
for clarity. Data are representative of 3 independent experiments.
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The ability of all Raf isoforms to mediate PMA/PKCα-induced growth suppressive ERK
signaling was further reinforced by analysis of the effects of PMA treatment on Raf heterodimer
formation. Immunoprecipitation of C-Raf in PMA-treated samples revealed increased association
of C-Raf with both A-Raf and B-Raf (Fig 3-12, C-Raf IP, right panel). A similar increase in CRaf/A-Raf and B-Raf/A-RAF complexes following PMA treatment was detected in A-Raf
immunoprecipitates (Fig 3-12, A-Raf IP, left panel). It should be noted that interpretation of these
results is complicated by the ability of PMA/PKCα to increase levels of A-Raf in 1% Ipegal CA630 (NP-40) lysates (Fig. 3-12, Input lanes). This increase, which occurred by 10 min of PMA
treatment, was not seen in whole cell lysates obtained using SDS solubilization buffer (e.g., Fig 311) and, therefore, does not reflect an increase in A-Raf expression. Instead, the effect likely reflects
increased solubility of A-Raf in the Ipegal-630 containing buffer used for immunoprecipitation.
Nonetheless, these data indicate that PMA/PKCα increases the levels of A-Raf containing
heterodimers in Ipegal 630-soluble compartments.

Although technical difficulties precluded

analysis of A-Raf and C-Raf in B-Raf immunoprecipitates by Western blotting, the data
collectively indicate that PMA/PKCα induces the formation of A-Raf/B-Raf, A-Raf/C-Raf, and BRaf/C-Raf heterodimers and that there is redundancy in the ability of Raf isoforms and dimers to
mediate PKCα-induced growth suppressive ERK signaling. Thus, selective Raf activation does not
specify growth suppressive ERK signaling pathways.
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Fig 3-12: Immunoprecipitation reveals that PMA/PKCα promotes the formation of A-Raf/BRaf, A-Raf/C-Raf, and B-Raf/C-Raf heterodimers
IEC-18 cells were treated with vehicle (EtOH) or 100 nM PMA for 30 min, followed by
immunoprecipitation using A-Raf and C-Raf antibodies. 10% of the original cell lysate (Input) and
immunoprecipitated samples (I.P.) were subjected to Western blotting for analysis of the expression
of A-Raf, B-Raf and C-Raf. Data are representative of >3 independent experiments.
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3.5 The Role of Ras Activity in Anti-proliferative ERK Signaling:
To assess the role of Ras proteins in PKCα-induced activation of ERK, we tested the effects of
salirasib, a farnesylcysteine mimetic (also known as FTS; farnesylthiosalicylic acid) that blocks
membrane association of activated Ras proteins by dislodging them from their membraneanchoring sites (Rotblat et al., 2008). As also shown in Fig. 3-3, both EGF and PMA/PKCα strongly
activate ERK in serum-starved IEC-18 cells (Fig 3-13). As expected, (Oda et al., 2005), salirasib
abrogated EGF-mediated ERK activation, which is known to be dependent on Ras activity; thus,
this experiment served as a positive control for the inhibitory effects of salirasib on Ras activity in
IEC-18 cells. Notably, salirasib also blocked the ability of PMA/PKCα to activate ERK (Fig 3-13)
and to modulate downstream targets cyclin D1, Id1 and p21 (Fig 3-14), pointing to a requirement
for Ras activity in growth suppressive ERK signaling.

Fig 3-13: Salirasib blocks EGF- and PMA/PKCα-mediated ERK activation
Serum starved IEC-18 cells were pretreated with 50 μM salirasib for 2 h, followed by 50 ng/ml
EGF or 100 nM PMA for 10 min and analysis by Western blotting. Data are representative of >2
independent experiments.
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Fig 3-14: Salirasib inhibits PMA-induced downregulation of cyclin D1 and Id1 and
upregulation of p21
Serum starved IEC-18 cells were pretreated with 100 μM salirasib for 2 h, followed by treatment
with 100 nM PMA for 2 h, and samples were analyzed by Western blotting. Data are representative
of 3 independent experiments.
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Since salirasib can have off-target effects (Baines et al., 2011; Blum et al., 2005; Goldberg
and Kloog, 2006; McMahon et al., 2005), the requirement for Ras in PKC agonist-induced
activation of ERK was further tested using a genetic “Rasless” embryonic stem cell model (MayorRuiz et al., 2018). This additional validation was particularly important because of the considerable
confusion in the field regarding the role of Ras in transducing signals from PKC to ERK, with some
studies indicating that PKC-mediated activation of Rafs is Ras-independent (Arai and Escobedo,
1996; Kolch et al., 1993; Ueda et al., 1996; Wen-Sheng, 2006). “Rasless” N-Ras-/-; H-Ras-/- ; KRasf/f ; Ubiq-CreERT2 mouse embryonic stem cells (mESCs) are knocked out for H-Ras and N-Ras,
and allow for conditional knockout of floxed K-Ras following activation of CreERT2; thus, they
lack expression of all three Ras isoforms following treatment with 4-hydorxytamoxifen (4-OHT)
(Mayor-Ruiz et al., 2018). As expected based on the established role of Ras in growth factorinduced ERK activation (Oda et al., 2005), complete loss of Ras in these cells is reflected in loss
of basal ERK phosphorylation (Fig 3-15, second lane). Prior to knockout of K-Ras, PMA treatment
readily increased ERK activation in these mESCs. A similar effect was seen with the short chain
DiC8, a more physiological PKC/PKCα agonist. However, following knockout of the remaining
Ras isoform, K-Ras, neither PMA nor DiC8 was able to induce ERK phosphorylation (Fig 3-15),
confirming the requirement for Ras activation in PKC agonist-induced ERK signaling. These data
also point to the ability of K-Ras alone to mediate PKCα-induced activation of ERK. Collectively,
these data indicate that, like growth factor-induced pro-proliferative ERK signaling, PKCα-induced
growth-inhibitory ERK signaling is mediated by activation of Ras in addition to Raf and MEK.
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Fig 3-15: PKCs require Ras activation to stimulate ERK in mESCs
N-Ras-/-; H-Ras-/- ; K-Rasf/f ; Ubiq-CreERT2 “Rasless” mESCs were treated with vehicle or 1 μM 4hydroxytamoxifen (4-OHT) for 7 Days to knock out K-Ras. The cells were then treated with 100
nM PMA or 20 μg/ml DiC8 for 15 min and samples were analyzed by Western blotting. Data are
representative of 3 independent experiments.

94

3.6 The Scaffold Proteins KSR1 and KSR2 are not Required for PKCα-mediated Growth Inhibitory
ERK Signaling:
The ERK scaffolding proteins, Kinase suppressor of Ras (KSR) 1 and KSR2 (Frodyma et al., 2017;
Rao et al., 2021), play an important role in modulation of pro-proliferative and oncogenic ERK
signaling (Kortum and Lewis, 2004), and have also been implicated in promoting ERK-dependent
differentiation (Kortum et al., 2005). siRNA knockdown experiments were, therefore, performed
to examine the role of these scaffolding proteins in PKCα-induced growth inhibitory ERK
signaling. Knockdown of KSR1 in IEC-18 cells did not affect the ability of PMA to induce a
reduction of cells in S-phase (Fig 3-16 (i), (ii)), indicating that KSR1 is not required for
PKCα/ERK-mediated G1→S arrest in these cells. Similarly, knockdown of KSR1 did not affect the
ability of PMA to downregulate cyclin D1 and Id1 or upregulate p21, further confirming that KSR1
is not required for growth inhibitory PKC-mediated ERK signaling (Fig 3-17). Since KSR2 is not
expressed in IEC-18 cells (Fig 3-18), these data indicate that PKC-mediated growth inhibitory RasERK signaling is not regulated by KSR1 or KSR2 scaffolding proteins.
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Fig 3-16: The scaffold proteins KSR1 and KSR2 are not required for growth inhibitory ERK
signaling

Fig 3-16 (i): Confirmation of KSR1 knockdown in IEC-18 cells
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Fig 3-16 (ii): KSR1 knockdown fails to affect PMA-induced G1→S phase arrest
IEC-18 cells were transfected with KSR1 siRNAs for 96 h prior to treatment with PMA for 6 h
followed by (i) Western blot analysis for the indicated proteins and (ii) flow cytometric analysis of
DNA content/cell cycle.

96

Fig 3-18: KSR1 knockdown has no effect on PMA-induced modulation of downstream targets
IEC-18 cells were transfected with the indicated siRNAs 72 h prior to treatment with PMA for 2 h
and Western blot analysis of the indicated proteins. Data are representative of 3 independent
experiments.

Fig 3-17: KSR2 is not expressed in IEC-18 cells

Western blot analysis of KSR2 expression in IEC-18 cells. Rat brain lysate is included as a positive
control.
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3.7 Association of PKCα with ERK Signaling Pathway Components:
Having excluded a role for KSR scaffolds in regulation of growth suppressive ERK signaling, we
examined the ability of PKCα to interact directly or indirectly with components of the ERK
pathway. Western blot analysis of PKCα immunoprecipitates with an antibody that recognizes all
Ras isoforms failed to detect interaction between PKCα and Ras, either before or after activation
of growth inhibitory signaling by PMA (Fig 3-19 (i)). Similar analysis also failed to detect
interaction between PKCα and MEK, total ERK or phosphorylated/active ERK in unstimulated or
PMA-treated cells (Fig 3-19 (i,ii)).
In contrast to the lack of interaction between PKCα and Ras, MEK or ERK,
immunoprecipitation experiments clearly and consistently detected association of B-Raf and C-Raf
with PKCα in unstimulated IEC-18 cells (Fig 3-19 (iii)). This interaction was confirmed in
reciprocal experiments in which B-Raf or C-Raf immunoprecipitates were probed for the presence
of PKCα (Fig 3-19 (iv)). Notably, PMA treatment reduced the interaction between PKCα and both
B-Raf and C-Raf (Fig 3-19 (iii, iv)) by 10 minutes, indicating that activation of growth-inhibitory
ERK signaling is associated with dissociation of PKCα/B-Raf and PKCα/C-Raf complexes.
Reciprocal immunoprecipitation experiments also consistently detected interaction
between A-Raf and PKCα in unstimulated cells, although the signal was weaker than for the other
Rafs (Fig. 3-19 (iii, iv)). It was not possible to determine the effects of PKCα activation on the
strength of this interaction because of the ability of PMA/PKCα to increase the levels of A-Raf in
lysates used for immunoprecipitation (Fig 3-19 (iii, iv), input). As discussed above, this increase
was not seen in whole cell lysates obtained using SDS solubilization buffer (e.g., Fig 3-11) and
likely reflects increased solubility of A-Raf in the Ipegal-630 containing buffer used for
immunoprecipitation. While the mechanism(s) underlying the increased solubility of A-Raf remain
to be determined, these data show that PKCα forms a complex with all three Raf isoforms and that
these complexes tend to dissociate during activation of growth suppressive Ras-ERK signaling.
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Fig 3-19: PKCα forms complex(es) with Raf proteins in unstimulated cells that dissociate following
PKC agonist treatment

Fig 3-19 (i): PKCα does not form a complex with Ras or ERK
IEC-18 cells were treated with vehicle (C) or 100 nM PMA for 10 min prior to lysis and
immunoprecipitation (IP) of protein complexes using a rabbit monoclonal PKCα antibody (Abcam
ab32376) (PKCα IP). Immunoprecipitates were analyzed for the indicated proteins by Western
blotting. Input represents Western blot analysis of 10% of the lysate used for immunoprecipitation.
Data are representative of 2 independent experiments.
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Fig 3-19 (ii): PKCα does not form a complex with total MEK, total ERK, or pERK
IEC-18 cells were treated with vehicle (C) or 100 nM PMA for 10 min. Lysates were subjected to
immunoprecipitation with either PKCα antibody (Ab221611) (PKCα IP) or IgG isotype control
(IgG IP). Immunoprecipitates were analyzed for the indicated proteins by Western blotting. Data
are representative of 3 independent experiments.

Fig 3-19 (iii): PKCα forms complexes with A-Raf, B-Raf, and C-Raf in unstimulated cells,
which dissociate upon PMA-induced PKCα activation.
IEC-18 cells were treated as in Fig. 3-19 (ii) and immunoprecipitates were analyzed for A-Raf, BRaf, and C-Raf by Western blotting. Data are representative of at least 3 independent experiments.
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Fig 3-19 (iv): Immunoprecipitation of A-Raf, B-Raf, or C-Raf confirms that PKCα forms
complex(es) with these proteins that dissociate following PKCα activation
IEC-18 cells were treated with vehicle (C) or 100 nM PMA for 10 minutes, lysed and subjected to
immunoprecipitation with anti-A-Raf, -B-Raf or -C-Raf antibodies. Immunoprecipitates were
analyzed for the indicated proteins by Western blotting. M: mock sample, lysis buffer treated with
antibodies pulled down with A/G-agarose beads. NS: non-specific band. Data are representative
of at least 3 independent experiments.
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3.8 Role of Ras Guanine Exchange Factors (GEFs) in PKCα-induced Growth Inhibitory ERK Signaling
3.8.1 SOS1 and SOS2 are not Involved in PKCα-mediated Growth Arrest in IEC-18 Cells:
Having established that PKCα intersects the canonical ERK pathway at Ras, we explored the
mechanism by which PKCα signaling activates Ras proteins. Initial experiments investigated the
role of Ras guanine exchange factors (GEFs) that control the GDP-GTP cycling of Ras family
members (Bos et al., 2007). Based on our RNA seq analysis of IEC-18 cells (Table 5), these studies
focused on SOS1, SOS2, and RasGRPs. Consistent with the established role of SOS1 and SOS2 in
growth-promoting signaling (Fuentes-Calvo and Martinez-Salgado, 2021; Guittard et al., 2015;
Liceras-Boillos et al., 2016), combined knockdown of SOS1 and SOS2 markedly reduced basal
ERK activity (Fig 3-20) as well as expression of cyclin D1 and Id1 (Fig 3-21). However,
knockdown of SOS1 and SOS2, either individually or in combination, did not affect the activation
of ERK induced by PMA treatment (Fig 3-20) and failed to affect the ability of PMA/PKCα to
further downregulate cyclin D1 and Id1 or to upregulate p21 (Fig 3-21), thus excluding a role for
SOS1 and SOS2 in growth-inhibitory ERK signaling downstream of PKCα.
While our analysis identified SOS1/2-independent growth suppressive PKCα–ERK
signaling, the data did not exclude the possibility that anti-proliferative PKCα–ERK signaling
intersects growth promoting ERK pathways through inhibition of SOS proteins. Follow-up studies,
therefore, examined the ability of PMA/PKCα to induce inhibitory phosphorylation of SOS1/2 by
ERK (Baltanás et al., 2020). To determine if PMA/PKCα alters the phosphorylation of SOS
proteins, we conducted Phos-tag gel analysis, which uses the Phos-tag™ molecule to specifically
capture phosphorylated proteins and retard their migration in SDS-polyacrylamide gels (Kinoshita
et al., 2012; Zheng et al., 2005). This analysis revealed that PMA had no effect on SOS2 migration
in Phos-tag gels (Fig 3-22 (ii)). However, PMA induced a PKCα-dependent change in SOS1
phosphorylation, indicated by a robust mobility shift that was prevented by the PKCα selective
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inhibitor Gö6976 (Fig 3-22 (i) upper and middle panel).

Notably, PKCα-induced SOS1

phosphorylation was also prevented by inhibition of ERK with SCH772984, indicating that the
effect is mediated by ERK (Fig 3-22 (i) bottom panel). Since ERK phosphorylation of SOS leads
to downregulation of growth factor signaling (Eblen, 2018), these data point to the possibility that
PKCα dampens pro-proliferative signaling in intestinal cells by promoting ERK-mediated
inhibitory phosphorylation of SOS1.

Table 5: RNA sequencing data reveals expres¬sion of SOS1/2 and RasGRPs in IEC-18 cells
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Fig 3-20: SOS1/SOS2 knockdown does not prevent PMA-induced ERK activation
IEC-18 cells were transfected with 100 pmol of non-targeting siRNA (NT) or siRNA targeting
SOS1 and/or SOS2. After 48 h, cells were treated with 100 nM PMA for 15 min and analyzed for
the indicated proteins by Western blotting. Data are representative of 2 independent experiments.
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Fig 3-21: SOS1/SOS2 knockdown does not affect PMA-induced modulation of downstream
targets
IEC-18 cells were transfected with 100 pmol of non-targeting siRNA (NT) or siRNA targeting
SOS1 and SOS2. After 48 h, cells were treated with 100 nM PMA for 2 h and analyzed for the
indicated proteins by Western blotting. The data are from a single membrane; the vertical line
indicates rearrangement of the lanes for clarity. Data are representative of 2 independent
experiments.
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Fig 3-22: PMA/PKCα alters the phosphorylation status of SOS
Upper panel of (i): IEC-18 cells were pre-treated with 4 μM Gö6976 or vehicle for 1 hr, followed
by addition of 100 nM PMA for 15 min. Middle panel of (i), IEC-18 cells were treated with 100
nM PMA for 15 min, cell were lysed and half of each lysate was treated with lambda phosphatase
(λPP) as indicated. Bottom panel of (i): same as upper panel (i), except cells were pretreated with
1 μM of SCH772984 or vehicle as indicated. (ii) Same as upper panel of (i). Lysates from all the
panels were run on Phos-Tag gels and analyzed by Western blotting for indicated proteins. Phostag™ is a functional molecule that specifically captures phosphorylated proteins and retards their
migration in SDS-polyacrylamide gels. The binding affinity relies on a dinuclear 1,3bis[bis(pyridin-2-ylmethyl)amino]propan-2-olato dizinc(II) moiety, acting as a “trap” for
phosphorylations. Data are representative of 3 independent experiments.
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3.8.2 RasGRP3 is Involved in PKCα-mediated Activation of ERK:
There are four isoforms of RasGRP, RasGRP1, 2, 3, and 4. RNAseq analysis showed barely
detectable levels of RasGRP1 mRNA in IEC-18 cells (Table 5) and Western blot analysis failed to
detect RasGRP1 protein in these cells (Fig 3-23). RasGRP4 was not detected in these cells. While
RasGRP2 mRNA is expressed in IEC-18 cells, this isoform does not activate Ras and fails to
respond to phorbol esters like PMA (Irie et al., 2004; Johnson et al., 2007; Kawasaki et al., 1998;
Stone, 2011). On the other hand, RasGRP3 mRNA and protein were readily seen in this model
[Table 5 and (Fig 3-24)]. Our studies, therefore, focused on the potential role of RasGRP3.
In contrast to SOS1/2, knockdown of RasGRP3 by siRNA consistently reduced the level
of ERK activation seen following PMA treatment (Fig 3-24), indicating that this GEF is at least
partially responsible for mediating PKCα activation of ERK. Interestingly, while RasGRP3
knockdown inhibited ERK activation by PMA/PKCα, the absence of RasGRP3 did not affect ERK
activation by EGF (Fig 3-25), supporting a role for RasGRP3 in anti-proliferative rather than
growth-promoting ERK signaling in intestinal epithelial cells. A compensatory role of
RasGRP1(Golec et al., 2013; Liu et al., 2007) was excluded since (a) Western blot analysis failed
to detect RasGRP1 in control or RasGRP3 knockdown cells, and (b) RasGRP1 knockdown, either
alone or in combination with RasGRP3 siRNA, did not affect the ability of PMA to activate ERK
(Fig 3-24).
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Fig 3-24: RasGRP1 protein expression is not detectable in IEC-18 cells
Lysates from IEC-18 intestinal cells and SW480 and FET colon cancer cells were analyzed by
Western blotting for the expression of RasGRP1.

Fig 3-23: RasGRP3 knockdown partially suppresses PMA/PKCα-induced ERK activation
IEC-18 cells were transfected with siRNA targeting RasGRP1 and/or RasGRP3 for 24 h, followed
by treatment with 100 nM PMA for 10 min and lysates were analyzed for the indicated proteins by
Western blotting. Data are representative of 3 independent experiments.
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Fig 3-25: RasGRP3 is important for growth inhibitory but not pro-proliferative ERK
signaling in the IEC-18 cell model
IEC-18 cells were transfected with 100 pmol of non-targeting siRNA (NT) or siRNA targeting
RasGRP3 for 24 h. NT and RasGRP3 knockdown cells maintained in normal serum (left panel)
were treated with 100 nM PMA for 10 min. NT and RasGRP3 knockdown cells serum-starved for
6 h (right panel) were treated with 100 ng/ml EGF. Lysates were analyzed for the indicated proteins
by Western blotting. Data are representative of 2 independent experiments.
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3.9 Loss of RasGRP3 Inhibits PMA/PKCα-induced Upregulation of p21:
Analysis of the effects of RasGRP3 knockdown on downstream targets of PKCα activation
revealed differential regulation of pro-proliferative cyclin D1 and Id1 proteins and anti-proliferative
p21. While RasGRP3 knockdown had no effect on the downregulation of cyclin D1 or Id1 seen
following PMA treatment, knockdown of this GEF markedly reduced the ability of PMA/PKCα to
upregulate p21 (Figs 3-26 and 3-27). Thus, these data indicate that induction of p21 by PMA/PKCα
is mediated by a RasGRP3-dependent Ras–ERK signaling pathway.
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Fig 3-26: RasGRP3 mediates PMA-induced upregulation of p21 in IEC-18 cells
IEC-18 cells were transfected with non-targeting siRNA (NT) or siRNA targeting RasGRP3 (ONTARGETplus SMARTpool siRNA) for 24 h, followed by treatment with 100 nM PMA for 15 min
for analysis of ERK activation (upper panel), or 2 h for analysis of readout proteins (lower panel)(i).
Lysates were analyzed for the indicated proteins by Western blotting. (ii) same as (i), except the
siRNA targeting RasGRP3 was from Invitrogen (Silencer Select pre-designed siRNA Rasgrp3).
Data are from single immunoblots; the vertical line indicates rearrangement of the blot for clarity.
Data are representative of 3 independent experiments.
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Fig 3-27: Loss of RasGRP3 significantly inhibits PMA/PKCα-induced upregulation of p21
Statistical analysis of three independent experiments from Fig 3-25.
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3.10 Effect of Loss of RasGRP3 on PMA/PKCα-induced Cell Cycle Arrest:
To confirm a role for RasGRP3 in growth inhibitory PKCα-ERK signaling, we examined the effect
of RasGRP3 knockdown on the ability of PMA/PKCα to inhibit G1→S phase progression, as
determined by changes in the percentage of cells in S-phase (Fig 3-28). Loss of RasGRP3 did not
affect the percentage of S-phase cells in untreated cells. However, knockdown of RasGRP3
significantly reduced the ability of PMA/PKCα to prevent G1→S progression, as indicated by a
higher proportion of S-phase cells in PMA-treated RasGRP3 knockdown cells compared with
PMA-treated control cells (p = 0.003, n = 3) (Fig 3-28). Together, these data indicate that a
RasGRP3–p21 signaling axis contributes to PKCα–ERK-mediated cell cycle arrest, with additional
contributions from RasGRP3-independent signaling that leads to cyclin D1 and Id1
downregulation. The role of RasGRP3-independent ERK activity in mediating PMA/PKCαinduced loss of cyclin D1 and Id1 was confirmed using the ERK inhibitor, SCH772984, in
RasGRP3 knockdown cells. As expected, pharmacological ERK inhibition abrogated PMA effects
on all readout proteins in these cells (Fig 3-29).
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Fig 3-28: A RasGRP3-p21 signaling module partially mediates PMA/PKCα induced cell cycle
arrest in IEC-18 cells
IEC-18 cells were transfected with non-targeting siRNA or siRNA targeting RasGRP3. After 24 h,
cells were treated with 100 nM PMA for 6 h and the percentage of cells in S-phase was assessed
by flow cytometry. n.s.: not statistically significant; *: p = 0.003, n = 3. Data are representative of
3 independent experiments.
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Fig 3-29: ERK inhibition abrogates PMA/PKCα-induced modulation of cyclin D1 and Id1 in
RasGRP3 knockdown cells
RasGRP3 was silenced in IEC-18 cells using siRNA. After 24 h, cells were pretreated with 1 μM
SCH772984 for 1 h to inhibit residual ERK activity, followed by treatment with 100 nM PMA for
2 h and samples were analyzed for the indicated proteins by Western blotting. Data are
representative of 3 independent experiments.
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3.11 RasGRP3 may be Phosphorylated by PKCα for Growth Inhibitory Signaling:
Phosphorylation of RasGRP3 by conventional PKCs has been shown to be important for RasGRP3
activation in B cells (Aiba et al., 2004; Zheng et al., 2005). Phos-Tag gels (Kinoshita et al., 2012)
were, therefore, used to detect changes in RasGRP3 phosphorylation upon PKCα activation.
Treatment of IEC-18 cells with PMA led to a reduction in the mobility of RasGRP3 in Phos-Tag
gels, pointing to an effect on phosphorylation (Fig 3-30 (i)). This shift was not seen when the lysates
were treated with λ-phosphatase, confirming that it reflects altered phosphorylation (Fig 3-30 (i)).
The shift was also inhibited by the classical PKC inhibitor, Gö6976 (Fig 3-30 (i)): since PKCα is
the only classical PKC in IEC-18 cells, these data support the conclusion that PKCα phosphorylates
and activates RasGRP3 in these cells. Importantly, the effects of PMA on RasGRP3 were
recapitulated by DiC8, a short chain DAG that represents a more physiological pharmacological
activator of PKC (Fig 3-30 (ii)).
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Fig 3-30: PMA/PKCα signaling alters the phosphorylation status of RasGRP3
(i) IEC-18 cells were treated with 100 nM PMA for 15 min. IEC-18 cells were pre-treated with 4
μM Gö6976, followed by treatment with 100 nM PMA (ii) or 20 μg/ml DiC8 (iii) for 15 min. Cells
were then lysed, and half of each lysate was treated with lambda phosphatase (λPP) as indicated.
Lysates were run on Phos-Tag gels and analyzed by Western blotting. *: shifted band. Data are
representative of 3 independent experiments.
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3.12 H-Ras Mediates PMA/PKCα-induced Upregulation of p21:
Next, we addressed the role of specific Ras isoforms in PKCα-induced activation of ERK. We
focused on H-Ras based on evidence that H-Ras plays a role in cell growth arrest/differentiation.
H-Ras levels are low in proliferating intestinal crypt cells and increase in post-mitotic,
differentiated cells of the intestinal mucosa (Furth et al., 1987). Consistent with a role in growth
arrest and differentiation, exogenous expression of H-Ras in CaCo-2 human colon cancer cells
decreased proliferation and promoted the expression of differentiation markers such as brush border
hydrolase genes (Celano et al., 1993). Furthermore, in the context of our data, RasGRP3 has been
shown to activate H-Ras in 293T cells (Yamashita et al., 2000). Based on these findings, we
analyzed the role of H-Ras in mediating PKCα–ERK dependent anti-proliferative signaling.
siRNA-mediated knockdown of H-Ras in IEC-18 cells resulted in a slight decrease in basal
ERK activity and reduced ERK activation in response to PMA, confirmed by a reduction in
phosphorylation of RSK (Fig 3-31). Thus, H-Ras appears to be partially responsible for activation
of ERK by PKCα. Remarkably, the effects of H-Ras knockdown on downstream proteins mirrored
those of loss of RasGRP3: while no effect was seen on PMA-induced downregulation of cyclin D1
or Id1, PMA-induced upregulation of p21 was abrogated in H-Ras knockdown cells. These data
identify at least two growth-inhibitory PKCα-activated ERK signaling pathways: one pathway
involving H-Ras that mediates induction of p21 and other(s) involving K-Ras and/or N-Ras that
mediates the downregulation of cyclin D1 and Id1.
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Fig 3-31: H-Ras is required for PMA/PKCα-induced p21 upregulation
IEC-18 cells were transfected with non-targeting (NT) siRNA or siRNA targeting H-Ras. 48 h later,
cells were treated with 100 nM PMA for 2 h and lysates were analyzed for expression of the
indicated proteins by Western blotting. NS: non-specific band. Data are representative of 3
independent experiments.
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3.13 The Growth Inhibitory PKCα–RasGRP3–H-Ras–ERK–p21 Signaling Module is also Triggered
by the more Physiological PKCα Agonist, DiC8, and is Seen in other Intestinal Cell Lines
To exclude the possibility that the differential effects of RasGRP3 on downstream targets of
growth-inhibitory ERK signaling are restricted to phorbol ester treatment, we tested the effects of
the PKC agonist, DiC8, a short chain DAG that also potently promotes PKCα-mediated cell cycle
arrest in IEC-18 cells (Frey et al., 1997). As shown in Fig. 3-32, RasGRP3 knockdown also
inhibited DiC8-induced ERK activation and p21 upregulation, without affecting downregulation of
cyclin D1 or Id1. These findings are consistent with the ability of DiC8 to promote a mobility shift
of RasGRP3 in Phos-Tag gels that was inhibited by the PKCα inhibitor, Gö6976 (Fig 3-30).
Importantly, the RasGRP3-dependent pathway mediating PKCα-induced p21 upregulation
was not restricted to IEC-18 cells as it was also observed in PMA-treated IEC-6 cells (Fig 3-33),
an independent non-transformed intestinal epithelial cell line (Quaroni and Isselbacher, 1981;
Quaroni et al., 1980). Furthermore, PMA treatment of PKCα-expressing SW620 colon cancer cells
fails to upregulate p21, in association with absence of RasGRP3, further supporting a role for
RasGRP3 in PKCα induction of this CDK inhibitor (Fig 3-34). Thus, a PKCα-induced RasGRP3/HRas-dependent growth-inhibitory ERK signaling pathway leads to upregulation of p21 in intestinal
epithelial cells, while an RasGRP3/H-Ras-independent ERK signaling pathway is responsible for
PKCα-induced downregulation of cyclin D1 and Id1 in these cells.
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Fig 3-32: DiC8 activates a PKCα–RasGRP3–H-Ras–ERK–p21 signaling module in IEC-18
cells
IEC-18 cells were transfected with non-targeting siRNA (NT) or siRNA targeting RasGRP3 for 24
h, followed by treatment with 20 μg/ml DiC8 for 15 min or 2 h. Lysates were analyzed for the
indicated proteins by Western blotting.
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Fig 3-33: PMA activates a PKCα–RasGRP3–H-Ras–ERK–p21 signaling module in IEC-6
cells
IEC-6 cells were transfected with non-targeting siRNA (NT) or siRNA targeting RasGRP3 for 24
h, followed by treatment with 100 nM PMA for 15 min or 2 h, and lysates were analyzed for the
indicated proteins by Western blotting. Data are representative of 3 independent experiments.
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Fig 3-34: Absence of RasGRP3 in SW620 colon cancer cells is associated with failure of
PMA/PKCα to induce p21 expression
IEC-18 and SW620 cells were transfected with non-targeting (NT) or RasGRP3 targeted siRNA
for 24 h, followed by treatment with 100 nM PMA for 15 min, and cell lysates were subjected to
Western blotting for the indicated proteins.
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DISCUSSION
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4.1 Discussion:
In this study, we have explored the mechanisms underlying PKCα-mediated ERK-dependent cell
cycle arrest. We have also compared PKCα anti-proliferative ERK signaling with pro-proliferative
ERK signaling induced by growth factors, drawing on EGF as an example. Using intestinal
epithelial cells as a model system, we have demonstrated that PKCα-mediated growth suppressive
ERK signaling requires the activity of all tiers of the canonical ERK pathway, including Ras small
GTPases, Raf kinases (MAPKKK), MEKs (MAPKK), and ERKs (MAPK). PKCα is dependent on
the activity of these effectors for downregulation of pro-proliferative downstream targets such as
cyclin D1 and Id1, upregulation of anti-proliferative proteins such as p21, and cell cycle arrest.
While there is no difference between PKCα and EGF in the requirement for major components of
the canonical ERK activation cascade, divergence was observed with respect to (i) the duration of
ERK signaling, with anti-proliferative effects of PKCα requiring a longer signal from the
MEK/ERK cascade (Clark et al., 2004), (ii) the requirement for PKCα signaling to engage
RasGRP3 activity for p21 upregulation, (iii) the specific involvement of H-Ras activity in PKCαmediated upregulation of p21, and (iv) the lack of involvement of the scaffolding proteins KSR1/2
in PKCα-induced activation of ERK. Collectively, our studies have identified a novel PKCα–
RasGRP3–H-Ras–Raf–MEK–ERK–p21 growth inhibitory signaling axis in intestinal epithelial
cells. Notably, while PKCα regulation of cyclin D1 and Id1 is also dependent on the ERK pathway
(Clark et al., 2004; Hao et al., 2011; Hizli et al., 2006; Pysz et al., 2014), effects on these molecules
were found to be independent of RasGRP3 and H-Ras activity. These findings indicate that PKCα
activates at least two Ras–ERK-dependent signaling pathways to promote growth arrest in IECs.
Although the Ras/Raf/MEK/ERK pathway is mainly thought of as a mitogenic and prosurvival signaling pathway with aberrant activity in epithelial cancers (Boulton et al., 1991; Boulton
et al., 1990; Hoshi et al., 1988; Ray and Sturgill, 1987), it is clear that the pathway can also promote
cell cycle arrest and cell death (de Jong et al., 2016; Shaul and Seger, 2007; Wei et al., 2020; Wu
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et al., 2020). These opposing physiological outputs appear to be determined by the strength and
spatiotemporal dynamics of the pathway. Compelling data in support of anti-proliferative functions
of the pathway comes from in vitro studies (Clark et al., 2004; Hao et al., 2011; Pysz et al., 2014;
Pysz et al., 2009; Traverse et al., 1994; Wu et al., 2020) as well as studies in animal models and
patient tumor samples (Braig et al., 2005; Collado et al., 2005; Michaloglou et al., 2005; Sarkisian
et al., 2007; Thaler et al., 2009) These studies have shown that growth-inhibitory
Ras/Raf/MEK/ERK signaling has significance in a variety of biological contexts, including
development, differentiation (e.g., neuronal), and even in cancer (Li et al., 2006b; Sun et al., 2015).
In this regard, oncogenic mutants of RTKs, Ras, or Raf can paradoxically lead to growth arrest in
both normal and tumor cells, suggesting that ERK pathway antiproliferative signaling may serve
to constrain tumorigenesis (Collado and Serrano, 2010; Courtois-Cox et al., 2008; Mooi and
Peeper, 2006)
Sustained activation of ERK1/2 is a hallmark of growth inhibitory signaling mediated by
the Ras/Raf/MEK/ERK cascade (Clark et al., 2004; Kerkhoff and Rapp, 1998; Raggatt et al., 2000;
Woods et al., 1997). PKCα-induced cell cycle arrest in intestinal epithelial cells also requires
prolonged activation of the ERK pathway (Clark et al., 2004), which is achieved by sustained
activation of PKCα. The physiological relevance of this pathway is supported by analysis of ERK
and PKCα activity in the self-renewing intestinal epithelium in vivo. Immunohistochemical studies
using phospho-ERK specific antibodies have shown that ERK is not only active in proliferating
crypt cells, but is also active in post-mitotic cells of the villus ((Heuberger et al., 2014), Michelle
Lum unpublished data, Fig 4-2). This finding was confirmed in a recent study using live imaging
approaches to detect ERK activity in unperturbed mouse tissues in vivo (Muta et al., 2018). Twophoton microscopy analysis of the small intestine of transgenic mice ubiquitously expressing a
FRET biosensor for ERK activity demonstrated that ERK is active in crypt as well as villus
epithelial cells, and activity is particularly strong at the crypt-villus transition where intestinal
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epithelial cells undergo growth arrest/differentiation. Notably, this strong ERK activity coincides
with membrane translocation/activation of PKCα which also occurs at the crypt/villus junction in
mice (Hao et al., 2011). Thus, the spatial distribution of PKCα activation and ERK activity in the
intestinal epithelium supports a model in which PKCα activates growth-suppressive ERK signaling
to (a) drive growth arrest at the crypt-villus junction and (b) maintain the post-mitotic state on the
villus.
A role for ERK pathway signaling in the post-mitotic compartment of the intestinal
epithelium is further supported by evidence that in vivo deletion of ERK1/2 in murine intestinal
epithelial cells (ERK1/2ΔIEC) promotes wasting, enterocyte dysfunction and loss of gut barrier
function, in association with crypt elongation and villus shortening (de Jong et al., 2016). Since
crypt elongation results from an increase in intestinal epithelial cell proliferation, these data indicate
that ERK1/2 signaling is required for precise regulation of cytostasis in the intestinal epithelium in
vivo. Similarly, dysfunction in the villus compartment indicates that ERK signaling is also
important for maintenance of post-mitotic intestinal cells, with evidence pointing to a role in
absorptive enterocyte maturation. Notably, a recent study in which ERK1/2 was deleted in the
mouse intestine during embryonic development using Villin-Cre (ERK1/2ΔIEC) also supports a
growth-suppressive role for ERK signaling in this tissue. Embryonic loss of ERK resulted in a
dramatic expansion of the intestinal stem cell population, as well as impaired secretory lineage
differentiation and enterocyte maturation, leading to embryonic lethality (Wei et al., 2020). Postnatal deletion of ERK1/2 also resulted in intestinal epithelial cell hyperproliferation and formation
of polyp-like structures in the small intestines of the mice. Together, these findings indicate that
ERK plays an important role in maintaining cellular homeostasis in the intestinal crypt and ensuring
normal differentiation and function of cells of the villus.
Major goals of this study were (a) to delineate PKCα-induced anti-proliferative ERK
signaling pathway(s), and (b) define crosstalk between PKCα and ERK signaling at a mechanistic
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level. Our studies clearly point to intersection of the ERK pathway by PKCα at the level of Ras.
Our previous studies showed that PKCα activation can promote GTP loading and activation of Ras
(Clark et al., 2004). Here, we have determined that Ras activation is required for PKCα-mediated
ERK-dependent cell cycle arrest. There has been long-standing confusion regarding the
requirement for Ras activity in PKC-mediated activation of ERK. Kolch, Rapp and colleagues
(Kolch et al., 1993) argued that PKCα can directly phosphorylate C-Raf at S499 for Rasindependent activation of C-Raf, both in vitro and in vivo, and that C-Raf S499A and S259D
mutants are defective for activation by PKCα. In contrast, Marshall’s group (Marais et al., 1998)
showed that C-Raf activation by PKC requires Ras activation and the formation of Ras-GTP/C-Raf
complexes. Subsequent studies by the Parker group (Schönwasser et al., 1998) demonstrated that
PKC-induced activation of C-Raf does not require phosphorylation at S499 and Wen-Sheng (WenSheng and Jun-Ming, 2005) reported that PKCα induces Ras- and Raf-independent activation of
MEK-ERK to inhibit the growth of hepatoma cells. Our data show that PMA/PKCα promotes CRaf phosphorylation at S338 (Fig. 3-9), a crucial site for C-Raf activation by PAK3 (King et al.,
1998). Conversely, phosphorylation at C-Raf S259 was reduced by PMA/PKCα. S259
phosphorylation is important for scaffolding protein 14-3-3 binding, which maintains Raf in
inactive state in absence of active Ras-GTP (Tzivion et al., 1998). To rigorously test the
involvement of Ras in PKCα-mediated activation of ERK, we used a combination of
pharmacological and genetic approaches. PKC activation failed to activate ERK in the presence of
the pan-Ras inhibitor salirasib and in “Rasless” mouse embryonic stem cells (H-Ras-/- ; K-Rasf/f ;
Ubiq-CreERT2 cells treated with 4-hydroxytamoxifen to knock out K-Ras). Together, the data
identify a requisite role for Ras activity in PKCα-mediated ERK activation in both intestinal
epithelial cells and mouse embryonic stem cells, and have thus established that PKCα intersects the
ERK signaling pathway at the level of Ras to induce growth inhibition in intestinal cells.
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IEC-18 cells express H-Ras, K-Ras and N-Ras. To define the Ras isoform(s) required by
PKCα to promote ERK-dependent growth arrest, we initially focused on H-Ras. Selection of this
isoform was based on evidence that H-Ras is highly expressed in post-mitotic/mature intestinal
cells (Furth et al., 1987) and that H-Ras signaling reduces proliferation and induces the expression
of differentiation markers in CaCo-2 colon cancer cells (Celano et al., 1993). Remarkably, we
observed that H-Ras is specifically required for PKCα-induced upregulation of p21 and that PKCαinduced loss of cyclin D1 and Id1 is independent of H-Ras activity. Interestingly, H-Ras is the least
frequently mutated Ras isoform in human cancer (4% vs 85% for K-Ras) and activating mutations
of H-Ras are not observed in colorectal cancer (Hobbs et al., 2016), perhaps reflecting a growth
inhibitory, differentiation-inducing function of this isoform in intestinal epithelial tissue. Since
loss of H-Ras did not affect PKCα-induced downregulation of cyclin D1 or Id1, additional studies
are required to address the role of other isoforms of Ras (K-Ras and N-Ras) in PKCα-mediated
ERK activation and growth arrest.
Having confirmed a requisite role for Ras isoform(s) in PKCα-induced growth arrest, we
explored the mechanism(s) mediating activation of Ras by PKCα signaling. Immunoprecipitation
data failed to demonstrate direct or indirect association of PKCα with Ras proteins. Therefore, we
explored the involvement of Ras guanine exchange factors (RasGEFs), focusing on SOS1/2 and
RasGRPs since our RNAseq data indicated that these are the only RasGEFs expressed in IEC-18
cells (Table 5). siRNA-mediated knockdown experiments excluded a role for SOS1/2, consistent
with their well-established functions in pro-proliferative signaling (Fig 3-20, 21). However, Phostag analysis revealed that PKCα induces ERK dependent phosphorylation of SOS1 (Fig 3-22(i).
While there is no evidence that SOS is a PKC substrate, multiple serine and threonine sites in the
C-terminal region of SOS1 are phosphorylated in response to growth factors, and phosphorylation
of five of these sites can be mediated by ERK itself (Corbalan-Garcia et al., 1996). ERK-induced
phosphorylation of three of these sites negatively modulates the interaction of SOS1 with Grb2,
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which is important for SOS function. Thus, in this scenario, it is possible that PKCα-induced
activation of ERK leads to phosphorylation of SOS1 and reduced binding of SOS1 to Grb2,
resulting in reduced growth factor-induced ERK signaling. Although our knockdown studies
indicate that growth inhibitory PKCα signaling does not require SOS1 or SOS2, it is possible that
negative regulation of SOS function contributes to downregulation of cyclin D1 and Id1 since the
expression of these molecules is normally maintained by mitogenic activation of ERK (Guan et al.,
2007; Hao et al., 2011; Hizli et al., 2006; Kamioka et al., 2010; Lake et al., 2016; Pysz et al., 2014).
Furthermore, an ability of PKCα to suppress SOS-mediated activation of ERK could account for
the observation that growth-inhibitory PKCα signaling is dominant over growth-promoting signals
in intestinal epithelial cells (Frey et al., 1997; Pysz et al., 2014).
Next, we tested the involvement of RasGRP3. RasGRP3 knockdown significantly reduced
PMA/PKCα-induced ERK activation, pointing to an important contribution of this RasGRP to
PKCα-mediated ERK-dependent growth arrest. Notably, the effects of RasGRP3 knockdown
mirrored those of H-Ras knockdown, abrogating p21 upregulation without impacting effects on
cyclin D1 or Id1. RasGRP3 has been shown to activate H-Ras in other systems such as 293T cells,
and in vitro studies with the RasGRP3 catalytic domain showed that RasGRP3 can promote GDP
release from H-Ras (Ebinu et al., 1998; Nagy et al., 2014; Yamashita et al., 2000). Importantly,
RasGRP family members have been implicated in negative regulation of cell proliferation in
intestinal epithelial cells, where RasGRP1 was shown to oppose EGFR-SOS1-Ras signals in crypt
cells through a negative feedback loop (Depeille et al., 2015). RasGRP1 was also shown to restrict
colorectal cancer cell growth in this study. Since RasGRP1 is not expressed in IEC-18 rat intestinal
crypt cells (Fig. 3-23), the data collectively indicate that both RasGRP1 and RasGRP3 have antiproliferative functions in the intestinal epithelium. However, the reliance of RasGRP1 on negative
regulation of SOS1-mediated signaling would indicate that these RasGEFs act, at least partially,
through separate mechanisms. Although RasGRP3 has been implicated in proliferation of breast
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cancer and melanoma cells (Chen et al., 2017; Nagy et al., 2014; Yang et al., 2011), we excluded
a requirement for this RasGEF in the proliferative ERK pathway regulated by EGF in IEC-18 cells.
Extensive studies on the regulation and function of RasGRPs have been conducted in
lymphocytes. RasGRP1 is important for T cell receptor (TCR) signaling, T cell development and
T cell maturation (Priatel et al., 2006; Priatel et al., 2002; Roose et al., 2005). RasGRP3 is
selectively expressed in B-cells, where it plays an important role in regulating Ras-mediated
signaling downstream of the B cell receptor (BCR) (Oh-hora et al., 2003; Teixeira et al., 2003;
Zheng et al., 2005). Like PKCs, the RasGRPs have a DAG/phorbol ester binding C1 domain and
DAG and PMA can redistribute RasGRP3 to the plasma membrane to induce Ras-GTP loading
(Lorenzo et al., 2001). Studies in lymphocytes further revealed that RasGRP1 and RasGRP3 are
phosphorylated by PKC at Thr184 (Priatel et al., 2002; Zheng et al., 2005) and Thr133 (Teixeira et
al., 2003; Zheng et al., 2005), respectively, and that PKC-mediated phosphorylation is required for
their activation and downstream signaling (Oh-hora et al., 2003). It is notable in this regard that our
Phos-Tag gel analysis revealed that PMA and DiC8 induce PKCα-dependent phosphorylation of
RasGRP3 in intestinal epithelial cells, findings that are consistent with evidence that the “classical”
PKC inhibitor Gö6976 can reduce Thr133 phosphorylation in DT40 B-cells (Aiba et al., 2004).
Taken together, our data and published literature suggest a model in which DAG/phorbol ester
treatment leads to membrane concentration of PKCα and RasGRP3, facilitating RasGRP3
phosphorylation and activation by PKCα.
Previous studies from our laboratory using Raf kinase assays demonstrated that PKCα
activates C-Raf (Clark et al., 2004). The current study extends this finding by determining the
requirement for Raf activity in PKCα-induced ERK activation and ERK-dependent cell cycle
arrest. Using pharmacological inhibitors and siRNA-mediated knockdown strategies, we
determined that PKCα is dependent on Raf activity for inhibition of cell cycle progression, that all
three Raf isoforms are activated by PKCα signaling, and that Raf family members play redundant
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functions in PKCα-mediated growth suppressive signaling. Such redundancy has also been noted
in pro-proliferative Raf signaling, although B-Raf/C-Raf heterodimers have the highest catalytic
activity and appear to predominate in Ras-mediated signaling in many systems (Freeman et al.,
2013b; Rushworth et al., 2006; Weber et al., 2001).
While extensive evidence supports a role for Rafs in promoting cell proliferation (An et
al., 2015), anti-proliferative roles have also been reported. Several early studies linked high activity
of Rafs with cell cycle arrest rather than proliferation. Studies in NIH3T3 cells demonstrated that
strong activation of A-Raf, B-Raf and C-Raf induced p21 expression and G1 phase arrest, whereas
low level activation of Rafs induced cyclin D1 and cyclin E expression and reduced p27 levels to
promote cell cycle progression (Woods et al., 1997). Similarly, activation of C-Raf in immortalized
human lung fibroblasts (IMR-90) led to irreversible cell cycle arrest along with an early onset of
senescence accompanied by p21 expression (Zhu et al., 1998).
Analysis of the Raf-interactome using the STRING tool (Search Tool for the Retrieval of
Interacting Genes/Proteins; http://string.embl.de), which collects information based on genomic
context, high throughput experiments, co-expression assays, and previous knowledge, identified
more than 200 proteins that form a complex with Raf proteins (An et al., 2015). Among these
proteins are members of the PKC family. PKCζ was shown to co-immunoprecipitate with C-Raf
in unstimulated cells and cells stimulated with PDGF, and to phosphorylate and activate C-Raf (van
Dijk et al., 1997). To our knowledge, our studies provide the first evidence for the presence of
PKCα-Raf complexes in unstimulated cells that dissociate at the plasma membrane following
PKCα activation. Using cell fractionation analysis, our laboratory has shown that the entire pool of
PKCα protein is cytosolic and inactive in unstimulated IEC-18 cells, translocating to the plasma
membrane within 1 min of PKC agonist treatment (Leontieva and Black, 2004; Saxon et al., 1994).
The Rafs are regulated similarly, localizing to the cytoplasm when inactive and associating with
the plasma membrane for activation (Surve et al., 2019; Terrell and Morrison, 2019). The
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interaction between PKCα and the Rafs seen in unstimulated cells must, therefore, occur in the
cytoplasm, with dissociation of PKCα-Raf complexes coinciding with activation-induced
membrane translocation. Thus, our reciprocal immunoprecipitation data suggest a model in which
PKCα-activating signals promote the translocation of PKCα/Raf complexes to the plasma
membrane, where PKCα is activated, releasing Raf proteins for activation by Ras.
We also explored the roles of the scaffolding proteins KSR1 and KSR2, well-established
regulators of the ERK pathway (Kortum and Lewis, 2004). These scaffolds do not appear to
regulate PKCα-induced anti-proliferative signaling: KSR2 is not expressed in IEC-18 cells and
KSR1 knockdown failed to prevent PMA/PKCα-mediated, growth-inhibitory ERK signaling,
modulation of p21, cyclin D1 or Id1, or cell cycle arrest. The ERK pathway is known to be
regulated by the spatial and temporal distribution of ERK pathway components. For example, Ras
signaling from the Golgi antagonizes malignant transformation (Casar et al., 2018), and the
RasGRPs are known to mediate Ras activation in the Golgi (Caloca et al., 2003). Thus, other ERK
scaffold(s) are likely to be involved; IQGAP1 is a strong candidate since it is known to be
phosphorylated by PKCα (McNulty et al., 2011). Future studies will, therefore, seek to understand
spatial and temporal aspects of PKCα-mediated growth inhibitory ERK signaling compared with
growth factor-induced pro-proliferative ERK signaling, to gain further insight into factors that
dictate the different outputs of stimuli that are mediated by activation of the same downstream
kinase.
Future studies will also define the signaling intermediates that link PKCα activation to
downregulation of cyclin D1 and Id1. As discussed above, one possibility involves PKCα-induced,
ERK-mediated phosphorylation of SOS and dissociation of SOS from Grb2, for inhibition of
growth factor-regulated expression of mitogenic molecules such as cyclin D1 and Id1. Another
potential mechanism involves regulation of RasGAPs by PKCα. The RasGAP neurofibromin (a
product of the NF1 gene) is an established PKC substrate that mediates neuronal differentiation
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Phosphorylation by PKCα increases the GAP activity of neurofibromin, thereby inhibiting EGFmediated proliferative Ras activity to promote growth arrest in glioma cells (Mangoura et al., 2006).
PKCs can also induce proteasomal degradation of neurofibromin to activate Ras (McGillicuddy et
al., 2009). In this scenario, PKCα-induced loss of RasGAP function would lead to activation of
Ras, specifying loss of cyclin D1 and Id1 expression for growth inhibition.
Based on our findings, we propose the following model(s) for PKCα-mediated antiproliferative ERK signaling in intestinal epithelial cells (Fig 4-1) For p21 induction (Fig. 4-1A):
(1) In unstimulated cells, PKCα exists in a complex with A-Raf, B-Raf, and/or c-Raf (as shown by
reciprocal immunoprecipitation experiments); (2) Accumulation of DAG/PMA in the plasma
membrane leads to membrane translocation of PKCα, a hallmark of PKCα activation, which
facilitates membrane localization of associated Raf proteins, (3) DAG/PMA accumulation also
leads to membrane association of RasGRP3, where it is phosphorylated and activated by
membrane-localized PKCα; (4) The RasGEF function of RasGRP3 promotes GTP-loading and
activation of H-Ras; (5) H-Ras induces Raf dimerization and activation, before or after release from
PKCα-containing complexes; (6) Raf then activates MEK and MEK activates ERK to induce p21
expression and partial cell cycle arrest. Our data, thus, identify a novel growth inhibitory PKCα –
RasGRP3 – H-Ras – Raf – MEK – ERK – p21 pathway in intestinal epithelial cells.
Complete cell cycle arrest requires additional regulatory events, such as downregulation of
cyclin D1 and Id1 (Fig. 4-1B). This could be achieved by PKCα-induced inhibition of growth factor
signaling. Potential mechanisms include (1) PKCα-ERK mediated negative regulation of SOSGrb2 binding or (2) PKCα-induced activation of RasGAPs such as neurofimbrin for inhibition of
growth factor-induced Ras activation. Alternatively, (3) PKCα activation may lead to inhibition of
GAP activity to enhance Ras activity and specify loss of cyclin D1 and Id1 by other mechanisms.
(4) PKCα regulation of cyclin D1/Id1 may involve K-Ras and/or N-Ras, or there may be
redundancy among K-, N- and H-Ras isoforms for this function.
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Fig 4-1: Model of PKCα mediated growth inhibitory signaling in intestinal epithelial cells

A, (1) Upon DAG/phorbol ester accumulation, PKCα-Raf complexes and RasGRP3 translocate to
the membrane, (2) PKCα then phosphorylates and activates RasGRP3, (3) RasGRP3 activates HRas, (4) H-Ras promotes dimerization and activation of Rafs, which dissociate from PKCαcontaining complexes, (5) Rafs activate the downstream cascade leading to p21 upregulation.
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B, (1) Activated PKCα may stimulate RasGAP activity, or (2) promote ERK-mediated inhibition
of SOS to dampen growth factor-induced expression of cyclin D1/Id1. Alternatively, (3) PKCα
may inhibit GAP activity to activate K- N- and/or H-Ras to specify ERK-mediated downregulation
of cyclin D1 and Id1 through other factors.
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Fig 4-2: pERK and PKCα immunostaining in murine intestinal epithelial tissues
(i) Phospho-ERK immunostaining of formaldehyde-fixed paraffin-embedded murine intestinal
epithelial tissue shows that ERK is active in both proliferating crypt cells (C) and post-mitotic villus
cells (V). Strong pERK staining is detected at the crypt/villus junction (J) where cells undergo
growth arrest (arrows).

(ii) Immunohistochemical analysis shows that PKCα is diffusely

distributed in the cytoplasm and inactive in proliferating crypt cells (C) and is recruited to the
plasma membrane, a hallmark of PKC activation, coincident with growth arrest at the crypt/villus
junction (J) (white arrows). PKCα remains membrane-associated/activated in post-mitotic cells of
the villus (V) (black arrows).
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4.2 Future Directions:
1. Determine the full PKCα-ERK pathway interactome. These studies will
involve use of magnetic bead-coupled antibody to immunoprecipitate PKCα and
associated proteins from control and PMA-treated IEC-18 cells. Eluted proteins
will be analyzed by Liquid Chromatography-Mass-Spectrometry (LC-MS/MS).
As a first step in this analysis, I have already performed initial standardization of
anti-PKCα antibody and control isotype matched IgG. Ongoing studies are
optimizing the immunoprecipitation conditions to enhance antigen recovery and
reduce non-specific binding of proteins to the antibody-conjugated beads.
2. Identify the Ras proteins involved in downregulation of cyclin D1 and Id1.
Building on our identification of H-Ras as the mediator of PKCα-induced p21
induction, knockdown strategies will be used to identify the Ras isotypes that can
mediate effects of PKCα on cyclin D1 and Id1.
3. Study the spatial and temporal localization of ERK pathway components
involved in PKCα-induced growth inhibitory signaling. Immunofluorescence
localization using total protein and phosphorylation-specific antibodies will be
performed to study alterations in the spatio-temporal regulation of endogenous
components of the ERK pathway following PKCα activation.
4. Examine the role of IQGAP1 and other scaffolding proteins in PKCαmediated ERK-dependent growth inhibitory signaling. siRNA mediated
knockdown will be performed to determine if IQGAP1 plays a role in the ability
of PKCα to promote ERK-mediated growth suppression and alterations in the
spatio-temporal regulation of components of the ERK pathway. If studies exclude
a role for IQGAP1, the involvement of other scaffolds will be examined. For
example, scaffolding protein Shoc2 is a known substrate of PKCα, that has been
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shown to regulate and activate ERK signaling (Jang et al., 2021; Lee et al., 2017).
CD82 is another scaffolding protein known to modulate and regulate sustained
PKCα mediated ERK signaling (Termini et al., 2016). Another candidate scaffold
protein is Annexin6; although its expression is low in epithelial cells, it has been
reported to stimulate p120GAP proteins to inhibit Ras signaling in breast cancer
cells (de Muga et al., 2009). Annexin6 is phosphorylated by PKCα and it stabilizes
H-Ras/p120GAP complexes to inhibit Ras–ERK signaling (Hoque et al., 2014;
Koese et al., 2013b).
5. Examine the role of RasGAPs in PKCα-ERK signaling. The effects of siRNAmediated

knockdown

of

PKCα-responsive

RasGAPs

(e.g.,

NF1)

on

RasGTP/RasGDP ratio will be assessed and Western blot analysis will be
performed to correlate observed effects with downstream targets of growthinhibitory ERK signaling, i.e., cyclin D1, Id1 and p21.
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